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CHAPTER I
INTRODUCTION
Cyclooxygenase
The 70 kDa cyclooxygenase (COX) enzyme provides a fascinating and 
industrially relevant point of focus for the computational studies described in this 
dissertation.  Described most simply, COX functions as a membrane-associated 
homodimer, catalyzing the committed step in the conversion of arachidonic acid (AA)  to 
prostaglandin H2 (PGH2), following AA's release from membrane phospholipds.  An 
overview of this reaction is depicted in scheme I-1 below:
Scheme I-1. COX synthesizes prostaglandin G2 (PGG2) from arachidonic acid at the 
cyclooxygenase active site.  PGH2 is reduced to prostaglandin H2 (PGH2) at the enzyme's 
peroxidase site.
COX is a binfunctional enzyme with two active sites.  At the cyclooxygenase 
active site, COX exquisitely controls the regio and stereo-selective bis-dioxygenation and 
cyclization of AA to form PGG2.  The reaction concludes at the entirely distinct 
peroxidase site, where intermediate PGG2 's C15 hydroperoxide is reduced to an alcohol 
to form PGH2.  The genome codes two 60% sequence-identical isoforms of COX.  Both 
COX-1 and COX-2 catalyze the same reaction, and the discussion which follows applies 
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to both.  COX-2 will be introduced in much greater detail later.  Figure I-1 below 
introduces the three-dimensional structure of COX.
Figure I-1. The three-dimensional structure of the COX homodimer assembly 
(1Q4G.pdb)  The COX globular domains are shown as brown and blue ribbons.  The four 
membrane-binding helices are shown in Magenta.  The competitive inhibitor α-methyl-4-
biphenyl acetic acid is bound in the cyclooxygenase active site, and rendered in CPK. 
Heme prosthetic groups at the peroxidase sites are shown in white sticks.
The COX reaction product PGH2 is unstable (Hamberg and Samuelsson 1973; 
Andersen and Hartzell 1984) and its bioactivity is imparted downstream by tissue-
specific synthases which swiftly convert PGH2 to other bioactive prostaglandins, as 
shown in Figure I-2 below.  These prostaglandins, in turn, bind to G-protein-coupled 
receptors and effect diverse biological responses (Funk 2001).
2
Figure I-2. Major prostaglandins produced from PGH2  
Figure used with permission of Hélène Juteau, Merck Frosst, Kirkland Quebec.
COX inhibitors (Aspirin being most famous) are therapeutically useful as anti-
inflammatory, analgesic, anti-pyretic, and anti-coagulant agents.  As a group, these 
inhibitors are commonly known as non-steroidal anti-inflammatory drugs (NSAIDs). 
The physiological impacts of NSAIDs result from the drop in downstream prostaglandin 
concentrations which follows COX inhibition.  To understand how COX inhibitors bind 
to the enzyme active site, it is helpful to review both the reactions catalyzed by 
cyclooxygenase, and the features that nature has evolved in the cyclooxygenase active 
site to bind arachidonic acid and tightly control its conversion to PGG2.
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Mechanism
Arachidonic acid (5,8,11,14-eicosatetranenoic acid or AA) has three bis-allylic 
methlyene carbons (C7, C10, and C13 are located between the cis double bonds).  These 
carbons are readily oxidized non-enzymatically, as abstraction of a hydrogen atom at any 
of these positions yields a planar pentadienyl radical.  In solution, O2 molecules can add 
to either face of this radical, at the first, third, or fifth carbon which bear the unpaired 
electron spin density.  Moreover, oxygen additions at the first or fifth carbon result in a 
final conjugated product which can be configured Z,E or E,E (Porter et al. 1980; Porter 
1986).  Thus, for each of the three bis-allylic methlyene carbons in arachidonic acid, an 
initial oxygenation can yield any one of 10 possible hydroperoxide products. 
Oxygenation is only one possible fate for pentadienyl radicals, which can also propagate 
through intramolecular abstraction of other labile hydrogens, forming rings.  Alternately, 
pentadienyl radicals can be quenched upon reaction with non-oxygen radical traps 
(Rouzer and Marnett 2003).
In contrast to these combinatorially diverse AA radical reaction products in 
solution, the enzymatic bis-dioxygenation and cyclization of AA at the cyclooxygenase 
active site is strikingly specific, yielding (nearly) exclusively PGG2.  Impressively,  key 
details of the cyclooxygenase reaction were unveiled by Samuelsson's radio-labeling 
experiments in the 1960s – long before the enzyme's isolation from tissue homogenates 
(Samuelsson 1965).  In part because of this work, he shared the 1982 Nobel Prize in 
Medicine.  Our current understanding of the mechanism is shown in Scheme I-2 below. 
In the following section, the mechanism will be discussed in greater detail, in the context 
of COX active site structural features.
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Scheme I-2. PGG2 is synthesized at the cyclooxygenase site through a free radical 
mechanism, in which two molecules of oxygen are added to arachidonic acid.  The final 
product, PGH2 is the result of a reduction at the distinct peroxidase site.
Active Site
A tour of the enzyme active site aids a rationalization of the COX reaction 
mechanism.  As suggested by scheme I-2, the first requirement for catalysis is a long, 
hydrophobic cavity to bind and anchor arachidonic acid in a bent conformation (Marnett 
and Maddipati 1991).  This cavity is provided by the globular domain of COX and it is 
shown as a translucent surface in Figure I-3.
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Figure I-3. The grey surface shows the arachidonic acid binding site in COX-1.  Key 
amino acid side chains are highlighted, and described in the text below.
Gly-533 frames the “top” of the cavity.  Mutations to bulkier residues at position 
533 render COX inactive against arachidonate, though mutant COX will still oxygenate 
shorter fatty acid molecules (Rowlinson et al. 1999).  At the the “bottom” of the AA 
binding cavity is the constriction site - a hydrogen bonding network consisting of 
Arg-120, Tyr-355, and Glu-524.  Structural and functional studies suggest that Arg-120 
forms a bidentate, charge-reinforced hydrogen bond with the AA carboxyl group, 
anchoring it for catalysis (Malkowski et al. 2000).   To accomplish specific radical-
mediated cyclization, the enzyme binds arachidonate in a bent “L shaped” conformation 
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that favors cyclization as an intermediate radical propagation step.  In radical form, 
Tyr-385 specifically abstracts the the pro-S hydrogen atom from C13 to begin the 
cyclooxygenase reaction.  Tyr-385 is ideally positioned for this, near the kink in the 
bound arachidonate (Rowlinson et al. 1999).  The cyclization step is accomplished in a 
region of the binding site that includes a number of hydrophobic residues.  Most notably, 
mutation of Leu-384 (or Gly-526) in this region of the binding site impedes the ability of 
COX to complete cyclization (Schneider et al. 2004).
Binding AA in a catalytically competent orientation is necessary, but insufficient 
to explain the reaction mechanism.  Tyrosine must be oxidized to a free radical before 
catalysis can begin.   Depicted in Scheme I-3, the initiation of the tyrosyl radical begins at 
the heme group bound near the COX peroxidase site.  There, cleavage of hydroperoxides 
activates COX via a two electron oxidation of the resting Fe3+ heme.  The resulting 
cationic, radical porphyrin binds Fe4+ coordinated to the freed atom of oxygen.  This 
radical system has significant oxidizing potential and removes one electron from Tyr-385 
to yield a tyrosyl radical.
Scheme I-3. Cleavage of hydroperoxides at the peroxidase site results in a two-electron 
oxidation of the heme prosthetic group.  A subsequent one-electron oxidation of Tyr-385 
creates the tyrosyl radical which initiates the cyclooxygenase reaction (scheme I-2).
Abstraction of the AA 13-pro-S hydrogen by Tyr-385 results in a pentadienyl 
radical, centered on C11, C13, and C15.  Next, oxygen adds to the pro-R face of C11. 
Prior computational studies by our group suggest that oxygen's preference for the pro-R 
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face of C11 is not only attributable to steric crowding of the other five possible reaction 
sites – but that it is also conferred by the specific channeling of oxygen to this reaction 
site.  Once a dioxygen radical has added to C11, its subsequent attack of the C8-C9 
double bond is kinetically favorable (Furse, Pratt, Schneider, et al. 2006).  C8 then attacks 
C12, closing the endoperoxide ring and forming an allylic radical centered on C13, C14, 
and C15.  The second oxygen is added at C15 with S stereochemistry.  The phenolic 
Tyr-385 hydrogen is abstracted by the oxygen radical, completing the synthesis of PGG2, 
and regenerating the Tyr-385 radical for another cycle of catalysis (Rouzer and Marnett 
2003).
 Mutagenesis implicates Ser-530 and Val-349 in the stereochemistry of the second 
oxygenation, as certain mutations at these positions strongly shift the COX product 
profile from 15S to 15R PGG2 (Schneider et al. 2002).  A model derived from a crystal 
structure suggests that Tyr-348, Phe-381, Tyr-385, and Ser-530 all work to sterically 
block oxygen addition to the opposite face of the allyl radical (Kiefer et al. 2000).  In 
ongoing research, we hope to shed additional light on the dynamics of the 
microenvironment around C15, and identify enzyme channels that may participate in 
PGG2 release.
Inhibition
 In order to out-compete binding of arachidonic acid, COX inhibitors must bind 
well to the cyclooxygenase active site.  This requires reasonable complementarity to the 
active site geometry and the pairing of ligand hydrogen bond donor/acceptors with active 
site residues (Miyamoto and Kollman 1993).  In light of the above tour of the COX active 
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site, and the reaction mechanism that it supports, the key structural components of 
common NSAIDs are not surprising.  Many inhibitors feature carboxylate moieties – and 
crystal structures have often, but not always, revealed these carboxylates to interact with 
Arg-120, as arachidonate does.  All COX inhibitors feature hydrophobic moieties which 
can favorably desolvate into the hydrophobic channel of the cyclooxygenase active site. 
Structures of a few representative NSAIDS are shown in Figure I-4
Figure I-4. Examples of COX inhibitors (NSAIDs)
Salicylic acid extracted from willow bark is a weak COX inhibitor – and was used 
as a pain reliever since antiquity.  Hoffman acetylated salicylic acid in the late 19th 
century to form the much more potent compound acetylsalicylic acid (aspirin),  arguably 
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the most successful pharmaceutical in history.  The 1982 Nobel Prize in Medicine was 
shared by John Vane for his revelation that aspirin reduces prostaglandin levels, by 
inhibiting COX (Vane 1971).  Structurally, the acetyl moiety of aspirin acetylates Ser-530 
and projects the acetyl group bulk into the COX active site, essentially inhibiting the 
enzyme irreversibly.  Other COX NSAIDs bind reversibly, through non-covalent 
interactions.
A diverse array of small molecule NSAIDs have been discovered.  Derivatives of 
the NSAID indomethacin are important to much of the research in this dissertation.  The 
crystal structure of indomethacin bound to COX-2 was solved to 3.0 Å.  (Kurumbail et al. 
1996) and key interactions of the bound inhibitor are shown in Figure I-5 below.
Figure I-5. Indomethacin bound to COX-2 (4COX.pdb).
On binding to the cyclooxygenase active site, indomethacin's carboxylate forms a 
charge-reinforced hydrogen bond to Arg-120.  The N-para-chlorobenzoyl moiety projects 
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“up” into the hydrophobic active site, and fills the same cavity where the cyclization of 
oxidized arachidonic acid occurs.
 All traditional COX inhibitors cause an unfortunate side-effect in many patients. 
Prostaglandin PGE2 (red in Figure I-2) plays a vital role in maintenance of gastric 
mucosa, and the prolonged ingestion of COX inhibitors is highly ulcerogenic.  Thus, for 
patients prone to ulcers, COX inhibition is an unsuitable strategy for long-term 
management of chronic inflammation which accompanies diseases like rheumatoid 
arthritis.
COX-2
In the 1980s, Needleman showed that cytokines and growth factors resulted in 
heightened COX expression (and activity) in fibroblasts (Whiteley and Needleman 1984; 
Raz et al. 1988).  In 1991, a Harvard team cloned a cDNA of this intriguing up-regulated 
COX enzyme, and revealed it to be 60% sequence identical to mammalian COX (Xie et 
al. 1991).  The following year, a UCLA team expressed this inducible enzyme in COS 
cells and showed it to have cyclooxygenase activity (Fletcher et al. 1992).  Two COXs 
(now named COX-1 and COX-2) with differing expression profiles were firmly 
identified (Feng et al. 1993) and it was subsequently reported that a COX-2 selective 
inhibitor reduced inflammation without reducing prostaglandin production in the stomach 
(Seibert et al.1994).  These data, in conjunction with a large number of other supporting 
studies, established and validated the COX-2 inhibitory hypothesis.  Namely, whereas 
COX-1 is constitutively expressed ubiquitously and most strongly associated with 
prostaglandin production in gastric mucosa and thromboxane production in platelets, 
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COX-2 is expressed primarily in the CNS and at sites of inflammation.  Thus, the 
development of COX-2 selective inhibitors should afford a therapeutic strategy for 
chronic inflammation treatment, without the gastric toxicity observed by non-selective 
inhibitors (Smith et al. 1996; Smith et al. 2000).
Val-523: The Billion Dollar Residue
Prior to reports of the first COX-2 crystal structures (Luong et al 1996), sequence 
analysis revealed that COX-2 was 60% identical to COX-1.  Visual inspection of an early 
COX-1 crystal structure (Picot et al. 1994) revealed a handful of COX-1/2 divergent 
residues which might impact the geometry of the enzyme active site.  Of several mutants 
constructed, the hCOX-2 V523I mutant was the most resistant to inhibition by the three 
COX-2 selective inhibitors assayed (Gierse et al. 1996).  The emerging opinion that the 
size of the 523 side chain was the critical determining factor in COX-2 inhibition was 
further supported by the V523A mutation, which retained sensitivity to COX-2 selective 
inhibitors (Guo et al. 1996).  
The structural basis for these functional results was confirmed with COX-2 
crystal structures (Luong et al. 1996) that showed the I523V substitution affords COX-2 a 
larger solvent accessible cavity in which selective inhibitors might bind (depicted in 
Figure I-6 below).
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Figure I-6. The solvent accessible surface of the COX-2 active site (compare to the 
COX-1 surface shown in Figure I-3).  Residue 523 is valine in COX-2 and isoleucine in 
COX-1.  This affords bound ligands access to an expanded “side-pocket” in the COX-2 
enzyme.
While V523I reduced the potency of the compounds vs. wildtype COX-2, potency 
against the mutant was not eliminated entirely.  And, the remaining inhibition was no 
longer time-dependent.  A reverse mutant of COX-1 (I523V) showed partially restored 
sensitivity to the COX-2 selective inhibitors, and the double mutation H513R/I523V 
completely restored sensitivity to time-dependent inhibition (Wong et al. 1997).  Shown 
in Figure I-7 below, the X-ray crystal structure of COX-2 selective inhibitor SC-558 
bound to COX-2 (Kurumbail et al. 1996) confirmed the hypothesis that a COX-2 
13
selective inhibitor could occupy the side-pocket space afforded by the “missing” 
methylene group of COX-2 Val-523.
Figure I-7.  COX-2 selective inhibitor SC-558 bound to the COX-2 active site 
(6COX.pdb).  SC-558 selectively inhibits COX-2  by occupying the additional space 
afforded by Val-523 (Ile in Cox-1)  Additionally, the sulfonyl moiety hydrogen bonds to 
the Arg-513 guanidinium group (513 is His in COX-1).  Unlike most non-selective 
inhibitors, this ligand does not contain a carboxylate, and makes no charged interactions 
with Arg-120.  Celecoxib has a methyl group where SC-558 has a bromine atom.
Two structures of the bound selective inhibitor SC-558 were deposited as the 
density did not allow for unambiguous orientation of the sulfonamide moiety of the 
ligand.  An excellent example of the role computation can play was demonstrated in a 
detailed free energy perturbation calculation which identified the SC-558 conformer in 
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6COX.pdb as having a more favorable set of ligand-protein interactions than the 
conformer in 1CX2.pdb.  Furthermore, assuming a rigid protein backbone around the 
active site, these calculations elucidated that Ile at position 523 forces SC-558 to adopt a 
less favorable torsion angle between its heterocyclic and phenyl-sulfonamide rings. 
Val-523 allows the two rings to relax an addition 12° away from co-planarity, to a lower 
energy conformation on average.  This small change is sufficient to impart a 1 kcal/mol 
enthalpic penalty in the binding free energy (Plount Price and Jorgensen 2000) and these 
energetics are likely a key component in the selectivity of all the commercial 
diarylheterocycle COX-2 selective inhibitors (shown below in Figure I-8).
Figure I-8. COX-2 selective, diarylheterocycle, inhibitors.
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The initial promise of COX-2 selective inhibitors was enthusiastically greeted by 
the marketplace.  The diarylheterocycles celecoxib (Celebrex) and rofecoxib (Vioxx) 
each achieved annual sales approaching US$5 billion.
Unfortunately, cardiovascular risks started to emerge in early, longer term studies 
of these compounds (Mukherjee 2001).  Rofecoxib (Vioxx) was removed from the 
market following cardiac events in a longer-term trial of the drug for the 
chemoprevention of benign sporadic colonic adenomas (Fitzgerald 2004)  Within days of 
withdrawing rofecoxib, Merck lost some US$25 billion in market capitalization. 
Celecoxib (Celebrex) continues to be sold, albeit with FDA mandated “black box” 
warnings.  Celebrex sales have fallen 70%.
Alternate COX-2 Inhibition Strategies
Cardiac risks aside, the diarylheterocycles validated the COX-2 hypothesis, that 
COX-2 selective inhibitors alleviate inflammation with greatly reduced ulcerogenicity vs. 
traditional NSAIDS.  Enzyme specificity is a known concern with the diarylheterocycles, 
as the sulfonamide-containing inhibitors celecoxib and valdecoxib can also inhibit 
carbonic anhydrase II (Weber et al. 2004).  Thus, it might be possible that undiscovered 
COX-2 inhibitors, based on novel scaffolds, or exploiting previously uncharacterized 
differences in the isozymes, may yield safe and more effective therapeutics.  These 
possibilities have, in part, motivated our ongoing computational research into COX, and 
we have endeavored to shed light on previously uncharacterized COX isozyme 
differences.  We should note that the current body of mechanistic evidence points to 
downstream reduction of PGI2 levels as the root cause of the coronary risk from extended 
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NSAID use – and thus cardiac risk is present even with non-selective NSAIDs 
(Fitzgerald 2007).  Nonetheless, COX remains an important pharmacological target, with 
many promising clinical trials underway as of this writing.  As one possible example of 
their therapeutic utility, COX-2 selective inhibitors may someday serve as cancer 
chemopreventatives (Gupta and Dubois 2001), and thus the risk of their administration 
may well be justified in some patient populations.  Furthermore, the insights we gain into 
the study of COX may advance our understanding of other complex, membrane-
associated enzyme systems.
One alternate molecular scaffold for the synthesis of COX-2 selective inhibitors 
has been traditional carboxylate-containing NSAIDs.  Derivatives of these long-
administered compounds might provide new inhibitors with proven safety and ADME 
profiles.  In light of early emerging evidence for a larger COX-2 active site,  synthetic 
chemists at Merck reasoned that bulkier derivatives of indomethacin might be COX-2 
selective inhibitors, and they discovered several.  Among them, indomethacin modified 
by the addition of chlorine atoms at the 1 and 5 positions of the para-chloro benzoyl ring 
(Figure I-9 below) is highly COX-2 selective (Black et al. 1996).
17
Figure I-9. The addition of steric bulk converts indomethacin to a COX-2 selective 
inhibitor.
In addition to active site volume differences, an intriguing difference between the 
COX isozymes is the role of Arg-120.  While the canonical NSAID binding motif 
features a bidentate charge-reinforced hydrogen bond between ligand carboxylates and 
Arg-120, the diarylheterocycles have no carboxylate moiety.  Through mutagenesis 
studies, Arg-120 is known to be required for inhibition of COX-1 by traditional NSAIDS 
– but it is not required for inhibition of COX-2 by the same compounds.  And, the methyl 
ester of indomethacin was reported to be a more potent inhibitor of COX-2 than COX-1 
(Greig et al. 1997).  Interestingly, while the R120Q mutant in COX-1 increases the 
apparent Km for arachidonic acid by 1000-fold (Bhattacharyya et al. 1996), the same 
mutation in COX-2 has no impact on the Km for AA, and actually increases the potency of 
COX-2 selective diarylheterocycles (Rieke et al.1999).
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Related to these observations, the Marnett group found that neutralizing 
indomethacin with bulky amides (or esters) frequently yields a COX-2 selective inhibitor 
(Kalgutkar, Crews et al. 2000), as shown in scheme I-4 below:
Scheme I-4. Coupling the free indomethacin acid to a bulky amine creates COX-2 
selective inhibitors.
The mCOX-2 V523I mutation was found to not impact the selectivity of these 
compounds.  With no obvious structural mechanism for the selectivity of these 
compounds, we employed computational methods to shed light on their structural and 
kinetic impacts.
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Dissertation Overview
Chapter II will introduce the “lobby” region of COX, the area enclosed by the 
four orthogonal helices in COX's membrane binding domain (magenta in Figure I-1).  In 
order for arachidonate (or inhibitors) to enter the active site, the compounds must exit the 
membrane, and transit through the constriction site to the cyclooxygenase active site. 
While most indomethacin-amides are COX-2 selective, the S enantiomers of 
α-substituted ethanolamide derivatives also inhibit COX-1.  COX-1 selective inhibitors 
also may have therapeutic value, as it was shown that COX-1 is over-expressed in some 
ovarian cancer cells, where it stimulates angiogenesis (Gupta et al. 2003).  Thus, a more 
detailed understanding of COX isoform differences could aid in the design of more 
selective, and potent, inhibitors of both COX isoforms.  The research reported in this 
chapter explores this intriguing stereoselectivity, and explains the observed IC50's of the 
inhibitors in terms of binding energetics.
Chapter III explores the role of position 472 in COX-2 selective inhibition. 
Residue 472 (Leu in COX-2, Met in COX-1)  is a “second shell” residue in all COX 
crystal structure.  As such it cannot make direct contact with bound indomethacin amides 
in the COX-2 active site.  However, Mary Konkle in the Marnett group identified this 
mCOX-2 residue, from many mutations she assayed, as slowing the on-rate of the 
indomethacin amides by up to 100x.  Our calculations have revealed a compelling 
explanation for her kinetic observations.
Chapter IV introduces ongoing research into the dynamics of the Cyclooxygenase 
channel network.  A great mystery in COX (as in many other enzymes with deeply buried 
active sites) is how the reaction product exits the enzyme.  This mystery is particularly 
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profound as experimental evidence suggests that PGG2 is shuttled to the peroxidase site. 
Analysis of channel opening events in molecular dynamics trajectories for COX with 
bound PGG2 and the precursor allyl radical yields some light on a potential product exit 
route.  A side-goal of this trajectory analysis is to better understand the dynamic 
component of the second oxygen addition, which COX remarkably constrains to the 
pro-S face of C15.
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CHAPTER II
ENANTIOSELECTIVE INHIBITION OF CYCLOOXYGENASE-1
Background
Previously, a wide range of ester and amide derivatives of the nonselective 
carboxylate-containing NSAID indomethacin were synthesized and found to selectively 
and potently inhibit COX-2 (Kalgutkar, Marnett, et al. 2000).   If these inhibitors bind to 
COX-2 in a manner consistent with the published crystal structure for the 
COX-2/indomethacin complex (Kurumbail et al. 1996), the indole ring C3 position side 
chain projects through a constriction site formed by the Arg-120/Glu-524/Tyr-355 triad, 
and into a cavity bounded by the four membrane-binding helices.  This cavity is 
commonly referred to as the “lobby” region in COX (Kalgutkar, Marnett et al. 2000) and 
is shown in figure II-1.
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Figure II-1.  The COX Lobby region (grey surface) is a cavity bounded by the four 
membrane-binding helices (purple).  In order to enter the active site, ligands must travel 
from the membrane, through the lobby, and pass between the three constriction site 
residues shown.
Two crystal structures for COX-2 complexes with selective inhibitors (zomepirac 
derivatives) have been published (Luong et al. 1996).  These crystal structures confirm 
that the zomepirac analogs do project into the lobby region, but specific interactions 
between these ligands and COX membrane-binding helix residues were not identified and 
the structures remain undeposited.  In one of these crystal structures, the typically 
observed constriction site triad is rearranged substantially.  The Glu-524 residue 
hydrogen bonds to Arg-513 rather than Arg-120, and the Arg-120 sidechain rotates away 
from the constriction site and hydrogen bonds to the backbone carbonyls of Glu-524 and 
Phe470.  The second half of the fourth membrane-binding “D” helix, which includes 
Arg-120, unwinds partially.  The Arg-120 Cα is displaced 2.3Å away from the active site, 
relative to other published COX crystal structures.  This conformational rearrangement 
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generates a notably larger binding pocket in the COX-2 isoform.  No COX-1/ligand 
complex crystal structures available to date exhibit a comparably enlarged binding site. 
Moreover, in COX-1, residue 513 is a histidine rather than an arginine, so it is possible 
that COX-1 cannot undergo comparable conformational changes.  If only the COX-2 
isoform is able to adopt an alternate, enlarged binding site conformation, this could 
explain the COX-2 selective inhibition observed for a wide variety of bulky indomethacin 
ester and amide derivatives (Kalgutkar, Marnett, et al. 2000).
An exception to COX-2 selective inhibition by indomethacin amide derivatives 
was discovered in the case of α-substituted indomethacin ethanolamides.  While α-(R)-
alkyl indomethacin ethanolamides are potent COX-2 selective inhibitors, α-(S)-alkyl and 
α-dimethyl substituted indomethacin ethanolamides inhibit both COX isoforms well 
(Kozak et al. 2002), as shown in Table II-1.
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Table II-1. Inhibition of wild-type cyclooxygenases by α-substituted indomethacin 
ethanolamides (Kozak et al. 2002).  The binding free energy for each ligand with COX-1 
is computed directly from the IC50 values.
α-
substituent
R S
Ovine COX-1
inhibition
IC50 (μM)
Human COX-2
Inhibition
IC50 (μM)
Estimated 
ΔGbind
to Ovine COX-1
 (kCal/Mol)
R-methyl CH3 H 33       0.17  -6.4
S-methyl H CH3 0.59 0.27  -8.8
R-isopropyl CH(CH3)2 H >63         0.11  > -4.6
S-isopropyl H CH(CH3)2 0.40 0.37  -7.7
R-phenyl C6H5 H 47        0.44  -4.7
S-phenyl H C6H5 <1.3     0.085 < -6.9
dimethyl CH3 CH3 0.80 0.19  -7.2
Here, we focus our attention on the COX-1 isoform, hypothesizing that COX-1 
does not undergo major constriction site reorganization or binding site expansion upon 
binding of indomethacin ethanolamides.  Our modeling studies suggest that the α-
substituted indomethacin ethanolamide derivative side chains interact with COX-1 
through a network of hydrogen bonds to Glu-524, Arg-120, and Tyr-355 and through 
hydrophobic interactions which involve primarily Pro-86, Ile-89, Leu-93, and Val-116 in 
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the lobby region.  Our studies further suggest that while both α-(R) and α-(S) 
stereoisomers can be accommodated well in the binding site, the α-(R) isomers must 
adopt an energetically strained conformation to form a comparable set of hydrogen 
bonding and van der Waals interactions with the enzyme relative to the α-(S) isomers.
Methods
Three-dimensional models for all indomethacin ethanolamide analogs listed in 
Table 1 were generated using crystal structure coordinates for indomethacin (Kurumbail 
et al. 1996) as a template.  A systematic search procedure was used to sample 
ethanolamide side chain conformations for each molecule, and all conformers were then 
energy minimized.  A clustering algorithm was used to eliminate redundant conformers 
(I.e., conformers with RMSD < 0.3 Å), and all remaining conformers within 8 kcal/mol 
of the global minimum energy conformation were retained for subsequent ligand docking 
studies.
Crystal structures for flurbiprofen methyl ester bound to ovine COX-1 (1HT5) 
and indomethacin bound to COX-2 (4COX) were used as reference structures to guide 
manual ligand docking exercises.  Protein backbone atoms for the COX-1 complex were 
superimposed onto the COX-2 reference structure (backbone RMSD = 0.86Å) to project 
a plausible reference position for indomethacin in the COX-1 binding site. 
Crystallographic waters, including active site waters, and detergent molecules observed 
in the 1HT5 structure were retained in all models.  The indole ring of each ethanolamide 
derivative was then superimposed on the indomethacin indole ring in this reference 
template.  Each ethanolamide derivative was shifted down in the binding pocket toward 
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the lobby region by ~1Å to improve ligand-protein contacts, as suggested by crystal 
structures for flurbiprofen and zomepirac derivatives with COX-2 (Luong et al. 1996). 
Binding site residue side chains were adjusted to reduce bad steric contacts with ligands, 
using a systematic conformational search procedure and a backbone-dependent side chain 
rotamer library (Dunbrack and Karplus 1993).  All ligand conformers with serious 
binding site steric clashes were discarded, and the remaining complexes were refined 
with energy minimization and limited, low temperature molecular dynamics to relieve 
any residual bad protein-ligand interactions.
Each refined complex was solvated with SPC/E water (Berendsen et al. 1987)  in 
a truncated octahedron periodic box, and two sodium cations were added for net charge 
neutrality.  Water and cation positions were relaxed with 1000 steps of conjugate gradient 
energy minimization, while keeping all protein, ligand, and detergent atoms fixed.  Next, 
all protein, ligand and detergent atoms were refined with 1000 steps of energy 
minimization, while water and counterions were held fixed.  Finally, the entire system 
was relaxed with 1000 additional steps of energy minimization.  The minimization 
procedure was followed by 20 ps of low-temperature molecular dynamics, allowing only 
water, ligand, detergent molecules and counterions to move freely.  A thermalization 
procedure was then used to prepare the system for equilibrium molecular dynamics 
simulation.  Initial velocities for each atom were assigned from a Boltzmann distribution 
at 310K, followed by a 0.2 ps MD simulation.  This procedure was repeated ten times 
with a different Boltzmann velocity distribution in each cycle, and then equilibrium MD 
simulations were run for each complex.  A weak harmonic restraint (20 kcal/mol/Å) was 
applied to tether the heme prosthetic group securely to its histidine ligand in each 
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monomer.  Each complex was equilibrated for several hundred picoseconds until total 
energies and structural fluctuations stabilized.  Various low energy configurations were 
selected from these initial MD trajectories, and used as starting points for subsequent, 
more extensive (1-1.5ns) equilibrium MD simulations, so that several trajectories were 
available for analysis for each complex.  The final 800 ps of each trajectory was used for 
subsequent energetic and structural analysis.
Standard AMBER all-atom potential functions were used for these calculations. 
Atom types and all necessary potential function parameters for ethanolamide ligands 
were assigned by analogy with existing parameters.  Optimized geometries for each 
ligand were obtained from Hartree-Fock calculations with a 3-21G* basis set.  Partial 
charges for each ligand were derived from ab initio molecular electrostatic potential 
calculations using a 6-31G* basis set, followed by fitting of the electrostatic potential to 
an atom-centered point charge model.  Charge fitting was constrained to insure that R and 
S stereoisomers had identical partial charge assignments.  The resulting ligand parameters 
are documented in Appendix A.  All energy minimization, molecular dynamics, energetic 
and structural analysis calculations were performed with the AMBER 7 suite of programs 
(Case et al. 2002).  A 1 femtosecond integration time step was used in all MD 
simulations, with a 9 Å nonbonded cutoff and partical-mesh Ewald summation to correct 
for long-range electrostatic interactions.  Relative ligand binding free energies were 
estimated using the MM-GBSA protocol in AMBER (Massova and Kollman 2000). 
Gaussian-98 was used for all ligand geometry optimization and molecular electrostatic 
potential calculations (Frisch et al. 1998), and partial charge fitting was performed using 
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the RESP program (Bayly et al. 1987).  The MDDISPLAY program was used for visual 
analysis of MD trajectories (Callahan et al. 1996).
Results and Discussion
Based on prior extensive mutagenesis experiments (Kozak et al. 2002), it is 
hypothesized that indomethacin ethanolamide derivatives inhibit COX via binding at the 
active site, and not through some secondary (i.e., allosteric) interactions with the enzyme. 
Thus, we have attempted to generate COX-1/ligand complexes that are consistent with 
the mutagenesis data, and that also help explain the stereoselectivity profile.
It is well known that small changes to ligand structure can result in dramatically 
different binding orientations, and the crystal structure of the inhibitor diclofenac bound 
to COX-2 reveals that it binds with its carboxylate group interacting with Ser530 and 
Tyr385, rather than Arg-120 as seen for all other carboxylic acid ligand complexes with 
COX published to date (Rowlinson et al. 2003).  Therefore, we chose to explore alternate 
active site orientations for each ligand.  Attempts to place the ethanolamide ligands in a 
“flipped” binding site orientation, analogous to the COX-2/diclofenac structure, 
invariably led to severe protein-ligand steric overlap, and it appears that these compounds 
must bind in a more conventional orientation.  Attempts were also made to rotate each 
ligand about the indole ring center of mass, but again these alternate ligand orientations 
produced serious steric clashes, and it appears that the ethanolamide derivatives’ binding 
mode must be rather similar to that observed in the COX-2/indomethacin crystal 
structure.
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In the initial model building process, the indole ring for each ethanolamide 
derivative was superimposed directly on the indole ring for the indomethacin template 
structure.  While the indole ring core fits nicely in the active site in this position, there are 
unfavorable steric interactions between the ethanolamide side chain and Arg-120, 
regardless of which low energy ligand conformer is docked.  Most of these unfavorable 
steric interactions were relieved by shifting the ligand indole ring ~1Å lower in the 
binding pocket towards the lobby region.  This ligand displacement toward the lobby 
region is consistent with crystal structures that exhibit a comparable shift between a 
zomepirac amide derivative and flurbiprofen in the COX-2 active site (Luong et al. 
1996).
Given a plausible placement and orientation for the indole ring core of each 
ligand, we explored potential interactions for the ethanolamide side chain in the lobby 
region.  As can be seen in Table 1, COX-1 can accommodate S-isomer derivatives with 
relatively small aliphatic side chain substituents (E.g., methyl, isopropyl) and the achiral, 
dimethyl analog, but larger alkyl or aryl substituents are not tolerated as well.  These data 
suggest that smaller aliphatic substituents likely interact with a small hydrophobic pocket 
somewhere in the lobby region.  Manual docking of low energy conformers for each 
ligand reveals that compounds with isopropyl substituents form favorable van der Waals 
interactions with a hydrophic pocket formed by lobby residues Pro-86, Ile-89, Leu-93, 
Val116 and the aromatic ring of Tyr-355.  The methyl and dimethyl derivatives also fit 
nicely, but compounds with larger substituents (E.g., phenyl) cannot be accommodated in 
this hydrophobic pocket without significant shifting of the ligand, and concomitant 
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disruption of favorable protein-ligand interactions.  These models thus provide a simple 
explanation for the ligand binding preferences as a function of side chain size.
While these models explain the size constraints for ethanolamide side chain 
substituents, they do not provide a clear explanation for stereoselective binding of these 
compounds.  Low energy conformers for both R and S isomers can fit well in the lobby 
region, forming a strong hydrogen bond between the side chain hydroxyl group and 
Glu-524.  Since manual ligand docking and structural refinement did not suggest any 
clear explanation for stereoselectivity control, we generated several relatively long (1-1.5 
ns) equilibrium MD trajectories for each complex to assess energetic contributions and 
stability of ligand-protein interactions.
We used the MM-GBSA protocol (Massova and Kollman 2000) to estimate ligand 
binding free energies from each equilibrium MD trajectory, and identified those 
trajectories yielding the most energetically favorable complexes for each ligand.  We did 
not compute entropy contributions explicitly, since the large size of these complexes 
makes normal mode calculations impractical, and the trajectories are not sufficiently long 
to obtain reliable entropy estimates from quasi-harmonic analysis.  However, we reason 
that the entropy contribution will be quite comparable for different trajectories of a 
particular ligand-enzyme complex, and probably for trajectories with different 
stereoisomers.  The entropy contribution might be comparable for all the ligand-enzyme 
complexes, since the ligands are all quite similar.  However, this is a rather tenuous 
assumption, and we therefore did not attempt to make any rigorous quantitative 
comparison of binding free energies for different ligands.  Total energies for the enzyme, 
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ligand, and the enzyme-ligand complex from the MM-GBSA calculations are listed in 
Table II-2 below.
Table II-2. MM-GBSA energy components for enzyme-ligand complexes.  Total energy 
values are listed for the enzyme, ligand, and enzyme-ligand complex (standard deviations 
are listed in parenthesis), and include the Generalized Born solvation contribution.  The 
binding energy estimate listed in column 4 is calculated as the total complex energy 
minus the enzyme plus ligand energies, but does not include the entropy contributions, 
and thus may be best regarded as a binding enthalpy estimate.  All values are reported in 
kcal/mol units.
Enzyme only Ligand only Complex ΔH  
R-methyl -26605.3 (89.0) 23.5 (4.8) -26640.5 (89.1) -58.7
S-methyl -26540.2 (86.7) 21.2 (5.5) -26576.3 (87.1) -57.3
R-isopropyl -26622.2 (90.5) 26.2 (5.2) -26658.4 (89.9) -62.4
S-isopropyl -26518.8 (93.2) 21.0 (4.8) -26561.4 (93.5) -63.6
Experimental ligand binding free energies for S-methyl versus R-methyl and S-
isopropyl versus R-isopropyl derivatives are listed in Table 1, calculated from the 
experimental IC50 values for these compounds.  It must be noted that a simple correlation 
between IC50 ratios and relative binding free energies is not strictly true for enzymes that 
exhibit complex binding kinetics, but we also note that excellent correlation for IC50 
values and computed binding free energies for celecoxib analogs was observed assuming 
this relationship in a previous study (Plount-Price and Jorgensen 2000).  As can be seen 
from the data in Table II-2, the energy component terms are quite large, and the statistical 
uncertainty for most terms is larger than the estimated binding free energy difference for 
R versus S stereoisomers.  Therefore, even if we did assume that the entropy 
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contributions are comparable for R- and S-stereoisomer complexes, we still cannot make 
definitive predictions about ligand binding preferences using these data.
Final energetic and structural results are derived primarily from analysis of these 
“energetically most favorable” trajectories, although all independent trajectories were 
considered in the analyses.  In each case, the MD trajectories exhibiting less energetically 
favorable complexes (i.e., less favorable ligand binding free energies based on MM-
GBSA calculations) involved complexes with higher ligand conformational strain energy, 
and are a direct consequence of our decision to build initial complex models with several 
low energy conformers for each ligand.  In many equilibrium trajectories, the strained 
ligand conformers relaxed to lower energy conformations, but in some trajectories the 
higher energy conformers appear to be effectively locked, because these higher energy 
ligand conformers facilitate optimal ligand-enzyme interactions.  Thus, we observe that 
the net ligand binding free energies calculated from these trajectories are a relatively 
subtle balance between ligand-enzyme interactions and ligand conformational strain 
energy.
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This balance of ligand-enzyme interaction energy with ligand conformational 
strain energy appears to successfully explain the stereoselective binding preferences for 
the ethanolamide analog series.  As can be seen in Table II-2, the ligand energies are 
consistently lower for S-methyl and S-isopropyl ligands than for the corresponding R- 
stereoisomers.  The solvation energy terms are essentially identical for ligand 
stereoisomers, so the ligand energy difference must reflect differences in conformational 
strain energies for R- versus S- stereoisomers in these complexes.  To investigate this 
possibility more thoroughly, we performed detailed energy decomposition and structural 
analyses for 800 configurations from trajectories of each enzyme-ligand complex.  The 
energetic analysis reveals that the R-methyl and R-isopropyl isomers do indeed have 
higher conformational strain energies on average than the S-methyl and S-isopropyl 
isomers as shown in Table II-3:
Table II-3. Total intramolecular strain energy for bound ligands.  The total intramolecular 
energy for each ligand is computed as the average over the final 800 ps of equilibrium 
molecular dynamics trajectories for each complex.  The intramolecular energy is a sum of 
bond stretch, angle bending, dihedral, and intramolecular van der Waals and electrostatics 
energy components (standard deviations are listed in parenthesis).  b The relative 
conformational strain energy for R versus S isomers is listed in column 3.  In each case, 
the S stereoisomer displays a more favorable conformational energy in the bound 
complexes.  All energies are reported in kcal/mol units.
R-isomer S-isomer ΔEb 
(R vs. S)
α-methyl ligands  58.4 (4.8) 56.3 (5.0) 2.1
α-isopropyl ligands 66.3 (5.2) 61.5 (5.1) 4.8
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While the energy fluctuations are reasonably large, as shown by the standard deviations 
in Table II-3, the trends observed over these trajectories are quite significant, and the S-
isomers consistently adopt lower energy conformations, as can be seen from the plots in 
Figures II-2 and II-3 , which follow.
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Figure II-2. Conformational strain energy for S-methyl and R-methyl compounds during 
the last 800 ps of equilibrium MD trajectories.  The S-Methyl isomer consistently adopts 
a lower energy conformation.  The conformational energies were calculated every 
picosecond and displayed as configurations 1-800.
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Figure II-3. Conformational strain energy for S-isopropyl and R-isopropyl compounds 
during the last 800 ps of equilibrium MD trajectories.  The S-Isopropyl isomer 
consistently adopts a lower energy conformation.  The conformational energies were 
calculated every picosecond and displayed as configurations 1-800.
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The energy decomposition analysis further reveals that the ligand-enzyme 
interaction energies are statistically indistinguishable for corresponding R- and S- 
isomers, as shown in Table II-4.
Table II-4. Enzyme-ligand interaction energies.  The enzyme-ligand interaction energies 
are computed as the average over the final 800 ps of equilibrium molecular dynamics 
trajectories for each complex (standard deviations are reported in parenthesis).  All 
energies are reported in kcal/mol units.
R-isomer S-isomer
α-methyl ligands -96.5 (3.2)   -94.1 (4.1)
α-isopropyl ligands -99.4 (4.6) -101.6 (4.7)
These results are consistent with the initial manual model building and structural 
refinement, which indicated that R- and S-stereoisomers formed equally good interactions 
with the enzyme.  The structural analysis shows clearly that the R-isomers on average 
adopt a more strained conformation than the corresponding S-isomers, as seen in Figure 
II-4. 
Figure II-4.  Newman Projections of R, S, and dimethyl α-substituded indomethacin 
ethanolamides, placing the amide nitrogen behind the Cα atom.  To bind to COX-1, 
R enantiomers must adopt a strained conformation in which the amide carbon is gauche 
to both the Cβ carbon and the alkyl substituent.  The S enantiomers can bind without 
enduring this additional strain.  The dimethyl compound adopts a gauche conformation 
similar to that of the R enantiomers, but this is the lowest energy conformation observed 
for the dimethyl analog.
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Basically, these analyses indicate that the R-isomers generally adopt a 
conformation that places both the ligand Cβ carbon and the methyl or isopropyl 
substituent gauche to the amide carbonyl carbon, while the S-isomers position the Cβ 
carbon and alkyl substituent gauche to the amide hydrogen.  In order to test whether these 
results might reflect bias in the original model construction and manual ligand docking, 
or simply inadequate configurational sampling in the MD simulations, we generated 
equilibrium MD trajectories starting with lower energy R-methyl and R-isopropyl 
conformers (i.e., conformations where the Cβ and alkyl side chains are positioned gauche 
to the amide hydrogen) docked in the binding site.  For these trajectories, there was no 
significant difference in ligand conformational strain energy compared to the S-isomer 
complexes, but the ligand-enzyme interaction energies were 6-10 kcal/mol higher (i.e., 
less favorable) compared to the earlier R-methyl and R-isopropyl complex trajectories. 
Together, these results suggest that the R-methyl and R-isopropyl compounds can indeed 
optimize binding site interactions, and ultimately yield lower binding free energies, by 
adopting slightly strained conformations.  The higher conformational strain energy for R- 
versus S-isomers correlates rather well with the experimental binding energies for R- 
versus S-isomers, and nicely explains the basis for stereoselective ligand binding in this 
ethanolamide analog series. 
The equilibrium MD trajectories also provide additional structural information for 
the complexes.  Several ligand-enzyme interactions are observed for all molecules in 
every trajectory, and probably represent the predominant, stabilizing interactions for the 
complexes.  The ethanolamide side chain hydroxyl group forms a hydrogen bond with 
Glu-524, and the side chain amide carbonyl oxygen accepts a hydrogen bond from 
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Arg-120.  These two hydrogen bonds are maintained consistently in all simulations.  The 
ligand side chain amide NH forms a hydrogen bond with the Tyr-355 side chain, although 
this hydrogen bond does fluctuate and occasionally breaks in some of the trajectories, 
particularly for the dimethyl derivative.  Lobby residues Pro-86, Ile-89, Leu-93, Val-116, 
and the aromatic ring of Tyr-355 make favorable van der Waals contacts with smaller 
alkyl substitutes in the ethanolamide side chain in all complexes, as shown below in 
Figures II-5 – II-7.
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Figure II-5. Stereoview of (A) α-(R) and (B) α-(S) methyl indomethacin ethanolamide 
ligand bound to COX-1.  Hydrogen bonds between ligand, protein, and crystallographic 
water are shown as dashed yellow lines.  The ligand also makes van der Waals contacts 
with lobby residues P86, I89, L93, and V116.  All figures were generated with the DINO 
program (Philippsen 2003).
41
Figure II-6. Stereoview of (A) α-(R) and (B) α-(S) isopropyl indomethacin ethanolamide 
ligand bound to COX-1.  Hydrogen bonds between ligand, protein, and crystallographic 
water are shown as dashed yellow lines.  The ligand also makes van der Waals contacts 
with lobby residues P86, I89, L93, and V116.
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Figure II-7. Stereoview of α-dimethyl indomethacin enthanolamide ligand bound to 
COX-1.  Hydrogen bonds between ligand, protein, and crystallographic water are shown 
as dashed yellow lines.  The ligand also makes van der Waals contacts with lobby 
residues P86, I89, L93, and V116.
The simulations suggest that the pocket size does not fluctuate dramatically, so 
that larger side chain substituents like a phenyl group cannot be accommodated quite as 
well, as shown in Figure II-8.
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Figure II-8. Stereoview of α-(S) phenyl indomethacin enthanolamide ligand docked in 
COX-1.  The ligand is rendered as a CPK structure, and the COX-1 lobby region is 
displayed with a translucent purple molecular surface.  The intersection of the ligand 
CPK surface with the lobby region residues I89 and V116 highlights the unfavorable 
steric interactions observed for the phenyl derivative.  The molecular surface was 
computed with the MSMS (Sanner 1996) program.
Water molecules also appear to play an important role in stabilization of the enzyme-
ligand complexes.  We retained crystallographic waters observed in the COX-1 reference 
structure used for all model building exercises, since it was easy to dock the 
ethanolamide derivatives in the binding site without removal of these waters.  During the 
simulations, some of these waters did shift positions, and waters near the entrance of the 
lobby region can migrate freely and/or exchange with bulk solvent.  Two water molecules 
are particularly well localized, however, and have important structural roles in the 
complexes.  One water molecule forms a stable bridging hydrogen bond between the 
Glu-524 backbone carbonyl oxygen and the Arg-120 guanidinium side chain, anchoring 
these two residues strategically in the binding site, where both form key interactions with 
all ligands.  This water molecule is present in the 1HT5 crystal structure, and although it 
exchanges occasionally with bulk water during our simulations, this particular water 
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molecule has a mean occupancy value of 1.0 in all trajectories and always forms this 
bridging hydrogen bond between Arg-120 and Glu-524, as observed in the crystal 
structure.  A second key water molecule is buried more deeply in the binding site and 
forms a bridging hydrogen bond between Tyr-355, His-90, and Glu-524 side chains in the 
1HT5 crystal structure.  However, in all our simulations, His-90 rotates away from the 
ligand binding site to eliminate an unfavorable electrostatic interaction with the indole 
ring methoxy group, and this water molecule then forms bridging hydrogen bonds 
between the ligand side chain hydroxyl or indole ring methoxy substituents and nearby 
protein side chains (E.g., Tyr-355) or backbone carbonyl oxygens (E.g., Pro-84).  While 
these hydrogen bonds fluctuate significantly during the simulations, this water molecule 
does remain well localized in the binding site (Figures II-5 - II-7).  Bulk water molecules 
do occasionally enter the binding site and make direct contact with this buried water 
molecule, so that exchange with bulk water should be possible.  However, we did not 
observe direct exchange with bulk water during the course of these simulations.
In summary, all ligands appear to form a consistent set of discrete interactions 
with enzyme binding site side chains.  Both R- and S-stereoisomers form comparable 
interactions with the enzyme, but the R-isomers do so at the expense of modest 
conformational strain.  The relative conformational stain energies for R- versus S- 
stereoisomers parallel the relative binding free energies for the stereoisomers extremely 
well.  There appears to be little size fluctuation in the hydrophobic pocket of the lobby 
region, explaining why ethanolamide derivatives with larger aliphatic or aromatic 
substituents do not bind as well.  Finally, it seems clear from these simulations that water 
molecules play a crucial role in stabilizing the ligand-enzyme complexes, either by 
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mediating ligand-enzyme hydrogen bonds or else by influencing enzyme side chain 
orientation in the binding site.
Other Proposals
The intriguing problem of selective inhibition of COX-1 by α-substituted 
ethanolamides has captured the attention of other research groups.  Following the 
publication of our hypothesis (Moth et al. 2003) a computational group in Korea 
employed automated docking, followed by free-energy perturbation of COX-2 V523I,  to 
develop an alternate hypothesis for enantioselectivity in the specific case of α-ethyl 
ethanolamides (Park and Lee 2005).  A troubling facet of this paper is that 
enantioselectivity is explained in terms of the perturbation of Val-523 to Ile-523. 
Experimentally, this mutation has been shown to have no impact on the stereoselective 
inhibition of α-substituted ethanolamides  (Kozak et al. 2002).
X-ray crystallography may have the greatest potential to explain the basis of 
enantioselectivity.  In 2007, following a lengthy refinement process, crystal structures of 
S- and R- ethyl ethanolamides were published and deposited (Harman et al. 2007).  In the 
case of the α-(R)-ethyl ligand, Harman's final adoption of a trans amide brought the 
inventory of ligand-protein hydrogen bonding contacts very close to our computational 
prediction.  As predicted, the X-ray model depicts the amide nitrogen donating a 
hydrogen bond to Tyr-355, the ethanol moiety donating a hydrogen bond to Glu-524, and 
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the amide substituents oriented gauche to the amide carbonyl.    On overlay of  Harman's 
R-ethyl structure with our prediction is shown below in Figure II-9.
Figure II-9. RMS backbone fit of Harman's COX-1 X-ray structure of bound α-(R)-ethyl 
indomethacin  (white) to our prediction for α-(R)-methyl indomethacin (magenta).  Both 
models depict Tyr-355 accepting a hydrogen bond from the amide nitrogen, and Glu-524 
accepting a hydrogen bond from the ethanol hydroxyl.  Small differences in the register 
of the indole ring are consistent with the high temperature factors deposited for the ligand 
and Arg-120.
We also predicted that the amide carbonyl would receive a hydrogen bond from 
Arg-120.  However, the register of the ligand atoms in the crystal structure does not 
depict any protein hydrogen bond to the amide carbonyl.  Harman's paper describes 
Arg-120 is shifted away from the active site, relative to other COX structures.  We had 
speculated that potent indomethacin-amide binding to COX-2 could well involve 
47
displacement of Arg-120 away from the active site, as shown in the first, undeposited, 
COX-2 crystal structures (Luong et al. 1996)  Thus, the small shift of Arg-120 in 
Harman's R crystal structure is not inconsistent with our analysis of previous COX-2 
structures, or our initial manual docking which required a small shift of Arg-120.  In fact, 
our Figure II-9 shows Arg-120 adopts a nearly identical conformation in both our average 
structure and the X-ray structure.  Relative to our prediction, the X-ray structure depicts 
an upward shift in both the ligand indole ring, and Tyr-355  in the crystal structure. 
These small differences in our static structures may be best explained by the dynamics 
which are conveyed in the X-ray structure deposition itself.  The 20YE.pdb structure 
diffracted to a resolution of 2.89 Å, and the temperature factors deposited for the key 
interaction points are quite high.  Temperature factors of 81.76  were calculated for all 
ligand atoms, 78.09 for Arg-120 side-chain atoms, and 89.48 for Glu-524 side-chain 
atoms.  Thus, our average computed structure and the deposited crystal structure are 
nicely consistent, given the structural fluctuations in the simulations and the large thermal 
fluctuations observed in the crystal structure.
In stark contrast to the similarity of our R enantiomer structures, the Harman's 
model pose of the S enantiomer structure (2OYU.pdb) is strikingly different from our 
prediction.  The amide substituents chains project into the side-pocket of COX-1, an area 
previously thought to be only accessible in COX-2.  The para-chlorobenzoyl moiety 
projects “down” into the lobby region, and the indole ring is rotated 90°  so that the 
methoxy group projects “up”  into the cyclization region of the active site.  
Computation of a density map for the R isomer structure is straightforward, but 
we have been unable to compute a satisfactory density map from the S isomer structure 
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factors.  Our calculations report an R-value of 0.359, which is much greater than the 
deposited R-value of 0.241.  An R-value of 0.359 suggests fundamental problems with 
the model, but conversations with Harman have reassured us that this R-value is an 
artifact of the alternate refinement software used for the S structure, and it does not 
indicate a flaw in the deposition of the model at the protein data bank.  With Harman's 
encouragement, we have proceeded to analyze the structure with our computed density.
Figure II-10. Omit map difference density contoured at 3σ with a 3 A boundary around 
the ligand.  Density computed using deposited structure factors and atomic coordinates.
(2OYE.pdb).  At this contour level, as in the Harman paper, there is no density around the 
chlorine atom, but density clearly extends into the side pocket.  Figure courtesy Joel 
Harp.  
As shown in Figure II-10 above (and Figure 2, panel A of Harman et al.), omit 
map difference density projects quite deeply into the “side pocket” of COX-1. 
Interestingly, no density is seen around the ligand chlorine atom.  Considering ligand 
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energetics more closely, the trans orientation of the para-chlorobenzoyl moiety relative 
to the indole is, from our quantum mechanical calculations in vacuum, 1.0 kcal/mol 
strained vs the cis orientation.
Figure II-11. Omit map difference density contoured at 1σ (blue) and 0.5σ (salmon). 
The ligand is docked with a the para-chlorobenzoyl moiety trans to the indole ring. 
Figure courtesy Joel Harp.  
Also energetically surprising is the conformation of the amide substituents in the 
side pocket of COX-1.  The Harman structure depicts a conformation gauche to the amide 
carbonyl, an orientation that we attributed to less potent binding in our studies.
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Conclusions
We have used model building and equilibrium molecular dynamics simulations to 
propose three-dimensional models for ovine COX-1 with a series of indomethacin 
ethanolamide derivatives, and to investigate energetic and structural aspects of these 
complexes.  Our modeling studies yield a detailed picture for the various inhibitor 
complexes that is consistent with available experimental data, and the calculations also 
provide a plausible explanation for the basis of stereoselective ligand binding for this set 
of molecules.  These calculations confirm that it is possible for COX-1 to bind 
indomethacin enthanolamide analogs without a significant structural rearrangement or 
expansion of the binding site region.  Results obtained in these modeling studies may be 
helpful in further defining some key features that govern COX-2 versus COX-1 isozyme 
inhibitor selectivity, and could be useful in future attempts to design inhibitors with 
increased isozyme selectivity.
At first glance, the X-ray structure appears to have both confirmed our predicted 
binding mode for the α-(R)-substituted ethanolamides, and fundamentally challenged our 
energetic arguments for enatioselective inhibition by COX-1 of the α-(S)-substituted 
ethanolamides.  However, the X-ray structures do not reveal a clear energetic rationale 
for the alternate binding orientations.  Harman suggests that the R-enantiomer cannot 
make the same ionic interactions with His-90 and Gln-192 without enduring a steric clash 
with the “roof” of the COX-1 side pocket.  But, we note that if the R enantiomer were to 
bind in this pose, the strain of the substituents to the amide carbonyl would be eliminated, 
and thus, roof interactions aside, the R should be the more potent inhibitor.  And, if the R 
enantiomer binds in the orientation that we both predicted, then surely the S enantiomer 
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must be able to adopt a similar orientation, with relieved ligand strain, if only as part of 
an ensemble of active ligand poses.  
The X-ray structures do not explain the binding mode of the α-dimethyl 
indomethacin ethanolamides, which inhibit COX-1 almost as well as the S-ethyl 
enantiomers.  Do they bind like R, like S, or something entirely different still?  It is also 
not clear from the crystal structure how bulkier α-(S)-isopropyl and α-(S)-phenyl 
derivatives can fit into the COX-1 side pocket as α-(S)-ethyl does.  The COX-2 V523I 
mutant had no impact on α-(S)-methyl binding, which is mysterious in light of the side-
pocket interactions.  Perhaps these ligands do indeed bind entirely differently to COX-2, 
as we suggested at the outset of our studies.  Perhaps ambiguities in the observed density 
maps have obscured more definitive answers to the enantioselectivity question.
In modeling an (R)-ethyl conformer into the side pocket, Harman suggests that the 
dynamics of inhibitor binding may be a more important factor in stereoselectivity than 
the final binding conformation, and that protein dynamics involved in ligand entry may 
be a critical determinant of indomethacin amide binding to COX enzymes.  This 
observation provides an excellent segue to our next chapter, which explores this 
conjecture in detail.
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CHAPTER III
THE L472M MUTATION IN COX-2
Background
The Discovery of L472M
The ester and amide derivatives of indomethacin are potent and selective 
inhibitors of COX-2.  This contrasts sharply with the parent indomethacin acid, which is 
a 15x more potent inhibitor of COX-1 than COX-2 (Kalgutkar, Marnett et al. 2000). 
When the Marnett laboratory first discovered that NSAID neutralization leads to COX-2 
selectivity, they also reported that mutation of COX-2 active site and lobby residues 
which are divergent from COX-1 do not significantly alter the selectivity of these NSAID 
amides.  Whereas the COX-2 V523I mutation dramatically reduces the potency of 
diarylheterocycles (Gierse et al. 1996), no such mutations of COX-2 conferred impotence 
on the inhibition of this series of compounds (Kalgutkar, Crews et al. 2000; Kalgutkar, 
Marnett et al. 2000).   Interestingly, mutagenesis of constriction site residues Tyr-355 and 
Glu-524 abolished the inhibitory potency of the NSAID amides.  However, these residues 
are conserved in both COX isoforms and thus while possibly giving clues about how the 
inhibitors might bind to COX, these mutations cannot account for the COX-2 selectivity 
of the series.  
Nonetheless, the generality of COX-2-selective inhibition by INDO-amides 
suggests that some fundamental difference in COX-2 vs COX-1 may account for the 
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behavior of the compound series.  To search for such determinants, the Marnett 
laboratory scanned divergent amino acids within 7 Å of the COX active site in a 
mCOX-2 background.  All the constructed mutants (V89I, I112L, Y115L, S119V, D125P, 
A151I, S471M, and L472M are depicted in Figure III-1 below) metabolized substrate 
with similar efficiency to wild-type enzyme.
Figure III-1. Location of Mutated Second-Shell Residues Relative to the COX Active 
Site Model illustrating the location of mutated second shell residues (V89I, I112L, 
Y115L, S119V, D125P, A151I, S471M, and L472M) using the 4COX crystal structure. 
L472 is highlighted in green.  INDO and remaining second-shell residues are shown in 
stick, carbon;gray, oxygen;red, nitrogen;blue, chlorine;magenta.  The constriction site 
residues (Arg-120, Glu-524, and Tyr-355) are shown with wire in magenta. 
Surprisingly, the only mutant that showed a significantly attenuated binding was 
L472M.  INDO amides amides were found to associate up to 48x slower to L472M than 
to mCOX-2.  This slower association rate corresponded well with IC50 measurements 
made using the TLC inhibition assay (Table III-1 below).
 Mutation of  residue L472 in COX-2 alters the selectivity of INDO-amides in a 
kinetically unique way.  In all cases, the neutral INDO derivatives were less potent 
against L472M.  The extent of potency loss (IC50(L472M) / IC50(mCOX-2)) ranged from 
3 to 92 (Table III-1). 
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Table III-1. Potency and selectivity of INDO-amides.  (Courtesy Mary Konkle, Marnett 
lab)
 *IC50 data are in nM.    †Selectivity index computed as ratio of potencies.
55
N
N
H
N
H
N
N
H
N
H
N
H
N
N
H
H
N
CF3
Br
CF3
Cl
Cl
1
6
2
3
4
7
5
Compound IC50*
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R
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>4000
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8
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>1000
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5
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4
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O
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R
O
M472L “Reverse” Mutation in COX-1
Though L472M metabolizes arachidonic acid as efficiently as mCOX-2, it could be 
argued that the mutant is simply deleterious to inhibitor potency, and is not a 
discriminating component of  COX-2/COX-1 selective inhibition.  To address this 
concern, Mary Konkle engineered the complementary mutation of M472L in a COX-1 
background, yielding a “reverse mutant.”  This COX-1 mutant was subsequently 
evaluated for its effect on INDO-amide inhibitor potency.  Although most neutral NSAID 
derivatives do not inhibit COX-1, a series of INDO ethanolamides have been reported to 
exhibit moderate COX-1 inhibitory activity.  Thus, (R)-2-(1-(4-chlorophenylcarbonyl)-5-
methoxy-2-methyl-1H-indol-3-yl)-N-(1-hydroxybutan-2-yl)ethanamide (2) was chosen as 
a probe for the impact of the M472L mutation in a COX-1 background.  This compound 
(2) displayed a 14-fold higher potency against the M472L reverse mutant than against 
hCOX-1 (Figure III-2), underscoring the obervation that residue 472 is a fundamentally 
important discriminant for COX-1 vs COX-2 inhibition
Figure III-2. Potency of 
Compound 2 against hCOX-1 
(IC50 = 20.1μM) and M472L 
(IC50 = 1.5μM) expressed in 
HEK293T cells with hCOX-1 
(triangles); M472L (squares). 
Experimental errors are s.e.m. 
Figure courtesy Mary Konkle, 
Marnett lab.
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Methods
Since there are no suitable unliganded COX-2 crystal structures to generate an 
initial model, we used structural results from previous MD simulations of a 
COX-2/indomethacin complex (based on the murine COX-2/indomethacin X-ray 
structure PDB ID 4COX) (Kurumbail et al. 1996), as reference.  We removed 
indomethacin from the enzyme active site, and also deleted the oligosaccharide residues, 
since the X-ray structural data for these residues is neither complete nor well 
characterized.  Hydrogen atoms were added to protein residues using the AMBER LEAP 
module (Case et al. 2006).  We then hydrated the empty enzyme active site and generated 
a solvation shell around the full protein homodimer using the Metropolis Monte Carlo 
program MMC (http://inka.mssm.edu/~mezei/mmc/) to place SPC/E (Berendsen et al. 
1987) water molecules at energetically favorable locations via a cavity-biased (Mezei 
1987 & 1989), Grand Canonical ensemble simulation (Marrone et al. 1998).  The COX-2 
dimer was centered in a rectangular cell 96 Å x 96 Å x 118.5 Å for the GCMC 
simulations, using the Amber94 potential function (Cornell et al. 1995) and a 7.75 Å 
solvent-solvent cutoff with minimal-image periodic boundary conditions.  Bulk water 
density was held at 1.0 g/ml in the outer 10 Å shell of the simulation unit cell.  Initially, 
we set the Adams B parameter (Adams 1975), which reflects the excess chemical 
potential of the simulation, to +1.5, allowing the simulation cell to flood with waters, and 
the B parameter was reduced subsequently to –1.70 over a series of MC runs.  Final water 
placement was then performed with an equilibrium MC simulation (6 x 107 steps), using 
every 30,000th configuration for water placement analysis.  Waters outside the first 
solvation shell were then removed, and 3,000 generic bulk water positions were 
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calculated using the Mezei and Beveridge algorithm (Mezei and Beveridge 1984) and 
data from the 2,000 saved ensemble configurations.
The hydrated COX-2 homodimer system was then solvated in a larger truncated 
octahedral box using the AMBER Leap module, and 10 Na+ counterions were added to 
impose net neutrality in the periodic unit cell.  A weak harmonic restraint (20 kcal/mol/Å) 
was used to tether the heme prosthetic group securely to the His388 axial ligand during 
MD simulations.  Water and cation positions were relaxed with 1000 steps of conjugate 
gradient energy minimization, while keeping all protein and heme, atoms fixed.  Next, 
protein and heme atoms were refined with 1000 steps of energy minimization, while 
water and counterions were held fixed.  Finally, the entire system was relaxed with 1000 
additional steps of energy minimization.  The minimization procedure was followed by 
20 ps of low-temperature (20K) constant-volume molecular dynamics, allowing only 
water, and counterions to move freely.  Next, a series of 10 short (0.2 ps) constant-
pressure MD simulations were run sequentially, assigning initial velocities for each 
separate simulation from a unique Boltzmann distribution at 310 K.  Then each system 
was equilibrated for several nanoseconds with NPT ensemble MD simulations. 
The mCOX-2 trajectory energies and structural fluctuations stabilized completely 
after 4.5 ns, and we extracted a configuration snapshot at 4.5 ns to generate the starting 
configuration for the L472M simulation.  We substituted the Met sidechain for L472, 
based on the Met side chain confirmation observed in COX-1 X-ray structures.  PDB IDs 
1Q4G (Gupta et al 2004) and 2AYL (Gupta et al. 2006).  Hydrogen atoms were added to 
the M472 side chain using the LEAP module, and the side chain geometry was relaxed 
using 1,000 cycles of conjugate gradient minimization, with all neighboring side chains 
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and solvent molecules held fixed.  We then equilibrated the M472 mutant system as 
outlined above.  We collected 20 ns of data from both the mutant and mCOX-2 
trajectories for subsequent analysis.
We used the AMBER99 (Wang et al 2000) all-atom potential functions for all 
simulations, with a 1 fs integration time step, a 9 Å real-space nonbonded cutoff and 
particle-mesh Ewald  summation to correct for long-range electrostatic interactions 
(Darden et al. 1993).
For quasiharmonic analysis of low-frequency dynamics (Levy et al. 1984; Amadei 
et al. 1993; Ota and Agard 2001; Ferrari et al. 2003), all waters and ions were removed. 
All side chain hydrogen atoms were stripped from the trajectory files, as high-frequency 
hydrogen motions were of no interest in these analyses.  Quasiharmonic vibrational 
modes and energies were calculated by the PTRAJ module in AMBER 9 (Case et al. 
2006).
Main channel radius analysis was performed with “channel_finder” a PERL script 
implementation of a protocol that has been described in detail previously (Furse, Pratt, 
Porter and Lybrand 2006).  Basically, “channel_finder” uses a series of iterative MSMS 
(Sanner et al. 1996) molecular surface calculations to determine the largest probe sphere 
that can escape from a designated starting point (e.g., the active site cavity) to the surface 
of the protein.  A collection of “blocker” spheres were first manually placed in the COX-2 
active site to exclude surface imaging of all but the main channel pathway leading from 
the active site, past the constriction site network, and into the protein lobby region.  For 
each trajectory snapshot, the initial probe sphere radius is set to 1.0 Å.  From there, 
channel_finder's binary search algorithm will next attempt to surface with a 1.5 Å sphere 
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if a channel is found, or 0.5 Å otherwise.  Subsequent attempts will add or subtract 0.25 
Å, 0.12 Å, and finally 0.065 Å from the converging probe sphere radius.  While we 
display frequency counts of all channel radii in our histogram (Figure III-4), we note that 
water molecules require a main channel radius of at least 0.7 Å to escape the active site. 
Moreover, with smaller probe spheres, the MSMS algorithm is less reliable and our 
blocker sphere set may not effectively constrain the probe escape route through the 
constriction site.  Thus, for these narrow channel observations, we simply classify the 
main channel as closed.  The initial MSMS probe spheres were always initially placed 
adjacent to Ala527 atom Hα in both monomers of both trajectories.  Extensive visual 
inspection of MSMS surfaces from every 50th frame revealed that probe sphere start 
position was reasonably constrained by the nearby backbone geometry throughout the 
entire trajectory, so that the probe sphere was indeed surfacing the active site region of 
interest.  While it is quite possible that our selection of start atom and blocking sphere set 
may have lead to occasional escape through alternate transient channels in the protein, 
our results are valid as a comparison tool as we precisely duplicate these channel finder 
parameters in the width calculations for each monomer of each trajectory, for all 19,000 
snapshots.
Visualization of MD trajectories and quasiharmonic vibrational modes was 
performed using MDDISPLAY its companion program NMDISPLAY (Callahan 1996). 
Static structure visualization was performed with PSSHOW (Swanson 1995).
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Structural Analysis of L472M
Inspection of Crystal Structures
Residue 472 is located in a turn that links two alpha helices comprised of residues 
463-470 and 478-482.  This turn is stabilized by a network of backbone hydrogen bonds 
that includes, in all COX crystal structures: 471N-468O, 472N-467O, and 470N-466O. 
Over the residue range 463-482, no pair of COX-2 X-ray structures exhibits a backbone 
RMSD greater than 0.4 Å and the 4COX structure we used for model construction has a 
backbone RMSD of 0.36 Å vs. the 2.0 Å COX-1 structures (2AYL and 1Q4G) (Gupta et 
al. 2004; Gupta et al. 2006).   In all COX crystal structures, Leu-472 and Met-472 are 
packed similarly, with a χ 1  dihedral angle of -60 ± 15°, and χ 2 of 180 ± 25°.  Residue 472 
is adjacent to the constriction site residue, Glu-524.  The invariant backbone and side 
chain geometry seen in this region of the enzyme allows easy superposition of all COX 
crystal structures.  However, visual and numerical analysis of superimposed COX-1 and 
COX-2 crystal structures reveals no significant structural differences in the region around 
residue 472.
Molecular Dynamics Simulation
Since the COX crystal structures do not exhibit any meaningful structural 
differences near residue 472, we postulated that the L472M mutation in COX-2 might 
induce a change in the dynamics of the enzyme, and we performed 20 ns molecular 
dynamics simulations and quasi-harmonic analysis for both wild-type and L472M mutant 
proteins to explore this possibility.  The RMSD for binding site residue backbone atoms 
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(vs. the 4COX reference crystal structure) is less than 1.3 Å for each monomer in both 
mCOX-2 and L472M simulations.   Typical COX hydrogen-bonding interactions among 
constriction site residues and transient bridging waters are preserved as seen in the crystal 
structures.  The backbone atom RMSD for residues 463-482, which includes the helices 
flanking residue 472, is less than 1.0 Å, relative to the 4COX crystal structure.  Simple 
distance analysis shows that the hydrogen bonds that stabilize the turn (residues 471-477 
discussed above) are present greater than 90% of the time during the simulations.  Leu 
and Met side chains maintain the same χ1 and χ2 torsion angles as seen in crystal 
structures, varying only ± 30°.  Side chain packing analysis shows that residue 472 is 
well-packed over the entire trajectories for both mCOX-2 and L472M mutant (Gregoret 
and Cohen 1990).
Quasi-harmonic Analysis
We performed quasi-harmonic analyses of both trajectories to examine more 
carefully possible changes in local dynamics conferred by the mutant.  The lowest 
frequency quasi-harmonic modes show clearly that L472M strongly impacts local 
dynamics in the constriction site region, as can be seen in the two movie files deposited 
with the electronic version of this dissertation.  In mutant enzyme, the lowest frequency 
modes manifest themselves as concerted motions of Glu-524 and Arg-120 side chains.  In 
the mCOX-2 enzyme, these motions are, by comparison, much less strongly coupled. 
To explore the structural effect these differential motions might have, we used our 
Channel_Finder utility  to conduct a frame-by-frame analysis of the width of the main 
channel that runs from the lobby region, through the constriction site, and into the active 
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site21.  The results, shown in Figure III-3, demonstrate that the constriction site opens 
much more widely and frequently in mCOX-2 compared to the L472M protein.  
Figure III-3. Main channel radii histograms for the mCOX-2 and L472M mutant MD 
trajectories.  Radii values are computed every picosecond over the final 19 ns of each 
trajectory.  While all radii values are displayed here, the channel is considered closed if 
the channel radius is smaller than 0.7 Å (the minimum navigable radius for a water 
molecule).
Thus, these channel width measurements reflect, structurally, the motions 
observed in the quasi-harmonic analyses.  The quasi-harmonic analyses and 
Channel_Finder results suggest that the L472M substitution alters local dynamics which, 
in turn, leads to further stabilization of the tightly bound constriction site residues and 
reduces the frequency of transient constriction site opening.  
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As noted above, the L472M mutation causes no statistically significant structural 
displacements in the protein backbone around residue 472 or any nearby residue side 
chains.  Indeed, the local protein geometry, including the residue 472 side chain 
orientation and packing, is highly conserved throughout both wild-type and mutant 
simulations, as well as in all published COX-1 and COX-2 crystal structures, and one can 
therefore easily superimpose all trajectory configurations onto a common backbone 
reference structure.  We then projected the low-frequency vibrational modes computed in 
the quasi-harmonic analyses onto this common backbone reference structure to examine 
the structural effects of the altered local dynamics.  The L472M substitution decreases the 
Glu-524 side chain fluctuations anisotropically by 0.2 - 0.3 Å, along an axis that projects 
from the residue 472 side chain through the Glu-524 side chain to the Arg-120 side chain. 
The Glu-524 side chain fluctuations in the orthogonal directions are unaltered between 
mCOX-2 and L472M mutant simulations.  This anisotropic reduction in Glu-524 side 
chain fluctuation effectively reinforces the Glu-524/Arg-120 hydrogen-bonding 
interaction, by diminishing the normal thermal fluctuation that would lengthen, or even 
transiently break, the Glu-524/Arg-120 hydrogen bond.  The mechanistic explanation for 
this effect is quite simple: the Met-472 side chain is slightly longer than Leu-472, as seen 
in Figure III-5, and thus physically reduces the range of motion possible for the Glu-524 
side chain along the Met-472/Glu-524/Arg-120 axis described above.  The ‘reinforced’ 
Glu-524/Arg-120 hydrogen bond in turn stabilizes the constriction site network and 
reduces the constriction site opening frequency and open-state diameter.
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Figure III-4. Leu-472 superimposed on Monomer A from a typical snapshot of the 
COX-2 Met-472 trajectory.  The constriction site residues are labeled.  Double-headed 
arrows display the change in anisotropic fluctuations of Glu-524, relative to the helices 
flanking position 472.    Along this axis, Glu-524 sidechain atoms fluctuate 0.2 to 0.3 Å 
less (yellow arrow) when adjacent to Met-472 (white), vs. mCOX-2 Leu-472 (white 
arrow).
Kinetic Analysis of L472M COX-2-Inhibitor Binding and Inhibition
The computational analysis suggests differential constriction site dynamics 
between wild-type COX-2 and L472M contributes to their differential sensitivity to 
inhibition by indomethacin amides.  To test this hypothesis, the Marnett lab performed 
steady-state and pre-steady-state kinetic analysis of COX-inhibitor binding.  INDO and 
INDO-esters and amides are slow, tight-binding inhibitors that exhibit a two-step kinetic 
mechanism for inhibition, as shown in the equation below:
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Concentration-dependent binding experiments were performed using N-(4-
bromobenzyl)-2-(1-(4-chlorophenylcarbonyl)-5-methoxy-2-methyl-1H-indol-3-
yl)ethanamide (3) to compare the kinetics of inhibition for mCOX-2 and L472M more 
closely.  The kobs values for L472M were dramatically reduced compared to those from 
mCOX-2 enzyme, which is consistent with reduced dynamics of inhibitor binding.
Figure III-5. Concentration dependence of the observed rate of association by 
Compound 3 with both mCOX-2 and L472M with mCOX-2 (squares); L472M 
(triangles).  Experimental errors are s.e.m.  (Figure courtesy Mary Konkle, Marnett Lab)
The KD values  calculated from these data were 0.34 ± 0.04 μM and 1.5 ± 0.09 
μM for mCOX-2 and L472M respectively.  These values corresponded closely to the KI’s 
for inhibition by 3 determined by radiochemical analysis (0.32 ± 0.03 µM and 1.8 ± 0.3 
µM, respectively). 
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Mary Konkle conducted pre-steady-state analysis of fluorescence quenching by 
compound 1 on a stopped-flow instrument to identify the k1 and k2 components of  kobs. 
The values of k1 and k2 were found to be the same magnitude in the cases of compound 1 
binding to both wild-type and mutant enzymes.  This is a key difference between 1 and 
INDO where k1>>k2 .  The plot of k1 vs. the concentration of compound 1 for each 
enzyme clearly showed a reduced rate constant for L472M compared to wild-type 
enzyme (Figure III-6).
B
mCOX-2 L472M mCOX-2/L472M
k1* 0.0360 ± 0.002 0.009 ± 0.001 4.00 ± 0.2
k2± 0.0270 ± 0.008 0.005 ± 0.004 5.40 ± 3.5
Figure III-6. (A) Concentration dependence of k1 for binding of Compound 1 to both 
mCOX-2 (triangles) and L472M (squares).  The slope of the lines are equivalent to k1. 
(B) presents the rate constants (k1 and k2) for binding of Compound 1 to both mCOX-2 
and L472M (* - µM-1s-1); († - s-1).  (Figure courtesy Mary Konkle, Marnett Lab)
  This is the first report of a COX mutation that slows the initial phase of inhibitor 
binding as reflected by k1.  Since k1 is slower than the diffusion-controlled limit, it 
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reflects both the bimolecular association of inhibitor with enzyme and its movement on 
the enzyme.  In addition to a reduced k1, k2 is reduced by approximately the same 
magnitude as k1 for L472M.
Discussion
The present study identifies a subtle difference between COX-1 and COX-2 that 
makes a significant contribution to the sensitivity of COX-2 to inhibition by neutral 
derivatives of INDO.  Conversion of the second-shell Leu residue at position 472 of 
COX-2 to the Met residue that is present in COX-1 decreases the inhibitory potency of a 
series of INDO amides relative to wild-type enzyme and decreases their rate of binding to 
the enzyme.  The reverse mutation of Met-472 in COX-1 to Leu increases the sensitivity 
of COX-1 to inhibition by INDO amide, 2.  Although the impact of the L472M mutation 
in COX-2 is dramatic for some INDO amides, its impact on others is less so, and it is 
clearly not the sole determinant of the COX-2 selectivity of this class of compounds. 
Nevertheless, it is the first residue of COX-2 in which a change to a COX-1 residue has 
any impact on binding and inhibition by INDO amides.  This includes a number of 
conserved first-shell residues that directly contact the inhibitors either in the active site or 
the lobby beneath it.
Examination of the crystal structures of COX-1 and COX-2 in the region of 
Leu-472 reveals no detectable differences in backbone configuration or side chain 
packing.  Thus, structural analysis alone is unable to shed light on the mechanism by 
which this conserved substitution alters inhibitor binding.  To probe the origin of this 
subtle but significant effect, we employed molecular dynamic simulations.  Our analyses 
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suggest that the L472M mutation alters low-frequency dynamical motions in the 
constriction site region, in a manner that effectively reduces the frequency and magnitude 
of constriction site opening.  We propose that this altered dynamical behavior impedes 
inhibitor binding to the enzyme.
Kinetic analysis of inhibitor binding to wild-type enzyme and L472M is 
consistent with the results of the molecular dynamics simulations.  The L472M mutation 
slows the rates of both the first and second steps of inhibitor-COX-2 binding that leads to 
tight association with the enzyme.  This is the first example of a mutation that has an 
effect on the first step of inhibitor binding, a step believed to represent a combination of 
the initial binding of the inhibitor to the enzyme and its movement through the 
constriction that separates the lobby from the active site.  This first step is normally much 
faster than the second step, which yields the final, tightly bound E-I* complex.  In the 
case of INDO, the second step is related to insertion of the 2’-methyl group of the indole 
ring into the hydrophobic depression in the side of the active site.  The fact that the 
L472M mutant exhibits a significantly reduced initial step of INDO amide binding 
implies that it has an effect on the movement of the inhibitor into the active site and is 
consistent with alterations in constriction site dynamics.
Our results are certainly unanticipated in light of the numerous COX crystal 
structures, which show clearly that either leucine or methionine can be accommodated at 
position 472 with no effect on equilibrium structure.  Substitution of Met for Leu is one 
of the most conservative observed in protein families, based on Blossum62 and PAM-250 
scoring matrices (Gonnet et al. 1992;  Henikoff and Henikoff, 1992), and it is rather 
striking that this conservative substitution could cause a nearly 100-fold decrease in 
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potency for some of these COX-2 selective inhibitors.  However, the possibility that non-
local effects, such as a point mutation, can impact ligand binding and/or enzyme function 
is not unreasonable.  Conformational gating due to fluctuating constriction site opening 
and closing events has been reported previously for enzyme-ligand binding reactions and 
there are recent reports that point mutations distal to the enzyme active site can have a 
notable impact on reaction rates, often due to alteration of equilibrium conformational 
fluctuations that increase the activation free energy barrier (Zhou et al. 1997; Billeter et 
al. 2001; Rod et al. 2003; Thorpe and Brooks 2004; Wong et al. 2005; Sergi et al. 2006). 
In light of these previous studies, our computational results and mechanistic hypothesis 
are quite plausible.  The specific details of our mechanistic hypothesis are novel, but it is 
likely that this type of behavior will be observed in many other gated ligand binding 
reactions as more enzyme complexes are analyzed.
Previous X-ray studies of COX-inhibitor complexes have not provided full 
rationalizations for analogous differential binding kinetics.  For example, flurbiprofen 
and methyl-flurbiprofen exhibit drastically different binding kinetics and time-
dependence of inhibition.  Yet, cocrystals of these inhibitors with COX-1 revealed 
virtually identical structures (Selinsky et al. 2001).  Active-site mutagenesis studies have 
revealed some functional aspects of COX-2 selective inhibition, but have not previously 
yielded insights into COX-2 inhibition by INDO-amides.  Our work here shows that the 
synergistic combination of crystallography, functional analysis, and computational 
techniques is required to tease out critical dynamical details from complicated systems, 
which currently challenge rational drug design.  Other examples of second-shell residues 
impacting ligand binding are an emerging trend.  Our approach should be extensible to 
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the study of these systems, and should provide a sophisticated strategy with which to 
address this important, expanding, area of scientific study.
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CHAPTER IV
CYCLOOXYGENASE MECHANISTIC INSIGHTS:
Second O2 Addition and PGG2 Exit Routes
Introduction
As shown in scheme I-2, the proposed cyclooxygenase reaction mechanism 
concludes with formation of an allylic radical (at carbons C13, C14, C15), addition of a 
second molecule of oxygen to the pro-S face of C15, reduction of the incipient peroxyl 
radical, and release of the resulting PGG2 to the peroxidase site (Rouzer and Marnett 
2003).  This chapter explores both COX's regio- and stereoselective control of the second 
O2 addition, and the PGG2 exit channels COX may provide so that this unstable molecule 
can transit to the peroxidase site.  Molecular dynamics trajectories, with the allyl radical 
(PGA) and PGG2 bound to the active site of both COX isoforms, have been run earlier, 
and the analyses reported here extend previous computational studies of the first COX 
oxygenation (Furse, Pratt, Schneider et al. 2006).
Second O2 Addition
Absent enzymatic (or other) control mechanisms, both faces of C13 and C15 
should be equivalently favorable sites for the second oxygenation in PGG2 synthesis. 
Yet, the second oxygen molecule is added exclusively to the pro-S face of C15.  From his 
X-ray structure of PGG2 bound in the active site, Kiefer argues that the second oxygen 
addition is favored at the pro-S face of C15 due to steric occlusion of the other three 
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reaction centers (Kiefer et al. 2000).  And, mutagenesis studies by Schneider demonstrate 
that the COX-2 substitutions V349I, S530T, S530M, and S530V, to varying extents, 
invert the stereo chemistry of the PGH2 product from 15S- to the bioinactive 15R- 
stereoisomer (Schneider et al. 2002).
To elucidate how COX dynamically controls the first oxygen addition, Furse 
conducted computational studies and found that cyclooxygenase employs a combination 
of oxygen channeling and steric shielding to drive the first oxygen addition to the pro-R 
face of C11 (Furse, Pratt, Schneider et al. 2006).  In the present work, we are extending 
Furse's studies to identify dynamic factors that impact the stereochemistry of the second 
oxygen addition.
PGG2 Exit Routes
The diffusion of substrates to enzyme active sites, and the release of reaction 
products are fundamental biochemical processes, necessary for life.  While X-ray crystal 
structures have yielded fascinating insights into the interactions of bound enzyme-
substrate and enzyme-inhibitor complexes, these structures have only infrequently 
revealed the routes by which small molecules transit to active sites.  In many cases such 
as COX, all crystal structures show that the active site is sequestered from the protein 
exterior.  Thus, we must conclude that ligand transit is only enabled by thermal 
fluctuations of the protein.  This reasoning was the impetus for early molecular dynamics 
explorations of oxygen's route to the myoglobin heme, which crystallography reveals to 
be encased in a well packed, hydrophobic pocket (Case and Karplus 1979).  While 
all-atom simulation of the system was not possible at the time, potential exit routes were 
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explored using a rigid protein model, and several, low barrier, concerted side chain 
rotamer combinations were identified as potentially creating paths for O2 and CO transit. 
Thus, protein dynamics were implicated in the lowering of energetic barriers to ligand 
transit. 
More recently, an all-atom molecular dynamics simulation of acetylcholinesterase 
identified a fast, dynamic, molecular gate separating external solvent and the channel that 
leads to the deeply buried enzyme active site.  The gating motion of a valine and glycine 
residue, in concert with the in-plane sliding motion of a tryptophan side-chain are 
described as being much like a camera shutter (Gilson et al. 1994).  In light of the 
relatively high turnover of enzymatic hydrolysis, and the catalytic demand for a substrate 
sequestered from bulk solvent, the “back door” gating model is a compelling picture for 
quick release of acetate and choline.
Direct comparisons between the dynamics of cyclooxygenase vs. 
acetylcholinesterase (or myoglobin) are potentially dangerous.  COX substrates and 
products are much larger molecules than acetylcholine.  And, the turnover number for 
COX (~60 molecules per COX dimer per second) (Smith et al. 2000) is at least ~100x 
slower than that of acetylcholinesterase.  However, mounting evidence from combined 
NMR/MD studies suggests that the ps-ns timescale fluctuations observed in MD 
simulations are connected to, and required for, the slower, larger scale motions that 
enable enzyme function (Henzler-Wildman et al. 2007).  Thus, while we might not see a 
dramatic channel opening in a 10 ns COX simulation, we should expect simulations to 
reveal transient local fluctuations which hint at larger-scale, kinetically relevant, channel 
fluctuations.
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 It is reasonably certain that arachidonic acid, following its release from the 
membrane, arrives at the cyclooxygenase active site by first traveling through the 
cyclooxygenase lobby, and then passing through the constriction site hydrogen bonding 
network.  However, the departure path of PGG2 and its route to the peroxidase site is a 
deeper mystery.  Early experiments show that membrane-associated (microsomal) COX-1 
preferentially reduces endogenous PGG2 vs. exogenous radio-labeled PGG2, whereas 
purified COX-1 enzyme reduces exogenous PGG2 just as efficiently (Eling et. al 1991). 
Eling's observations suggest a role for the membrane in the shuttling of PGG2 to the 
peroxidase site and they have provided much fuel for the musings of crystallographers. 
Daniel Picot outlines three proposals for the transit of PGG2 (Picot 1998).  First, 
he postulates that PGG2 could directly diffuse through the enzyme.  But, he discounts this 
idea as X-ray structures reveal no suitably wide channels in the enzyme.  Next, he 
speculates that the increased hydrophilicity of PGG2 (vs. arachidonate) would make it 
unlikely for PGG2 to return to the membrane for passive release into the luminal space 
and diffusion to the peroxidase site.  Third, he gently promotes the idea that PGG2 could 
return to the lobby, and escape through a “small window” from there into the luminal 
space.  Picot also notes that elucidation of the structural determinants of PGG2 transport 
could potentially lead to development of a dual cyclooxygenase/peroxidase inhibitor. 
Thus, our computational research in this area may stimulate more than just academical 
interest.
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Regio- and Stereospecificity of the Second Oxygen Addition
Results
As with Furse's studies of the first oxygen addition, spin localization has the 
potential to play a role in the specificity of the second oxygen addition.  If COX were to 
twist the allylic radical out of plane, that would localize unpaired spin density at a 
specific face of C13 or C15, making it a favorable site for oxygenation.  Thus, we have 
reconsidered the possibility of spin localization in the context of the allylic radical. 
Across both COX-1 and COX-2 PGA trajectories, the allyl radical is planar on average, 
and the standard deviation from this planarity is less than 9°.  This planarity is not 
surprising, as the quantum mechanical calculations which Furse employed to 
parameterize the allyl radical exhibited a rotation barrier of at least 16 kcal/mol (Figure 
IV-1 below).
Figure IV-1. 16+ kcal/mol allyl radical rotation barrier calculated with density functional 
theory at the B3LYP/6-31G* level of theory.  Mulliken spin density analysis for the C13-
C15 allyl radical intermediate in PGG2 synthesis is shown at 10° intervals.  Figure 
courtesy Kristina Furse and Derek Pratt.
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To explore steric shielding as a possible mechanism, Furse's protocols for 
measuring the accessibility of the top and bottom faces of C13 and C15 have been 
extended to consider not only enzyme atoms, but also PGG2 ligand atoms, as visual 
inspection of trajectory snapshots suggests that these atoms occlude oxygen access to 
spin density at C13.  The resulting computed accessibility estimates are shown below in 
Figure IV-2.
Figure IV-2. Average free space estimates. The amount of empty space along the “top” 
and “bottom” of the allyl radical carbons (C13-C15) in the COX-1/PGA and COX-2/PGA 
trajectories is indicated by the height of the bars. The top face (blue bars) is defined as the 
face exposed to Tyr-385 (pro-S face of C15); the bottom face (red bars) is defined as the 
face exposed to Ser-530 (pro-R of C15). The carbon atoms are represented by cyan 
spheres.  The calculations revealed no free space around the bottom face of C13 and C15 
(with the neglible exception of COX-1 monomer B).  This results from frequent close 
intermolecular contacts of other PGA atoms with the bottom face of the allyl radical.
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The average accessibilities shown in Figure IV-2 directly reflect Kiefer's 
observations of the static crystal structure – that the pro-S face of C15 is the least 
occluded reaction center of the allyl radical.  However, it is noteworthy that the nearest 
neighbor atoms are somewhat variable in these dynamic trajectories.  The bottom of C13 
is most often self-occluded by other atoms of the PGA intermediate itself.  This self-
occlusion is seen in ~65% of all trajectory snapshots.  The remaining trajectory frames 
are primarily occluded by Ser-530.  The top face of C13 is more accessible, but Tyr-385 
occludes C13 in at least ~65% of each monomer trajectory.  An exception to this is 
COX-1 Monomer B, where Tyr-385 and Trp-387 atoms are closest atom to C13 in ~80% 
of the snapshots.  The bottom of C15 is also primarily occluded by other PGA atoms – in 
about 50% of the snapshots for each monomer.  Ser-530 occludes the bottom face in 
approximately 25% of the snapshots.  In some trajectories, Leu-530 and Leu-534 interact 
in this area.  In others, residues 202-206 play a role in occlusion of the bottom face.
Val-349 has been identified as a critical determinant of C15 oxygenation 
stereochemistry (Schneider et al. 2002), though it is not packed adjacent to C15 in any 
crystal structures.  This has prompted speculation that the PGA reaction intermediate 
must be quite unlike arachidonic acid, foreshortening to bring C15 into contact with 
Val-349 (Schneider et al. 2007).  To test this hypothesis, and reveal details of the 
registration of intermediates in the active site, we measured key inter-atom distances 
across all our trajectories (between Gly-533 Cα at the top of the channel and C20; 
Val-349 Cβ and C15; Ser-530 Cβ and C15) and the results of these measurements are in 
Tables IV-1 – IV-3 below.  As can be seen in Table IV-1, there is no indication in our 
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simulations that the PGA intermediate shifts laterally in the COX binding pocket, 
suggesting that the "foreshortening" hypothesis is unlikely.
Table IV-1. Distances between Gly-533 Cα at the top of the COX archidonate binding 
site and C-20.
Bound
Species
COX-1 
Monomer A
COX-1 
Monomer  B
COX-2 
Monomer A
COX-2 
Monomer  B
ACD 4.1 (0.3) 4.9 (0.5) 3.9 (0.3) 3.9 (0.3)
RAD 4.1 (0.3) 4.0 (0.3) 4.1 (0.4) 4.0 (0.3)
PGA 4.0 (0.3) 4.0 (0.3) 3.9 (0.3) 4.0 (0.3)
PGG 4.0 (0.3) 4.4 (0.5) 4.0 (0.3) 3.8 (0.3)
Table IV-2. Distances between Ser-530 Cβ and C-15.
Bound
Species
COX-1 
Monomer A
COX-1 
Monomer  B
COX-2 
Monomer A
COX-2 
Monomer  B
ACD 4.3 (0.4) 5.2 (0.2) 4.9 (0.4) 5.8 (0.4)
RAD 4.8 (0.3) 5.0 (0.3) 4.3 (0.3) 5.3 (0.4)
PGA 4.3 (0.3) 5.3 (0.3) 4.2 (0.3) 5.2 (0.3)
PGG 4.1 (0.2) 5.1 (0.6) 4.2 (0.4) 5.5 (0.9)
Table IV-3. Distances between Val-349 Cβ and C-15.
Bound
Species
COX-1 
Monomer A
COX-1 
Monomer  B
COX-2 
Monomer A
COX-2 
Monomer  B
ACD 7.1 (0.7) 9.5 (0.6) 6.6 (0.6) 6.7 (0.7)
RAD 7.9 (0.6) 7.6 (0.4) 7.2 (0.5) 8.3 (0.7)
PGA 6.1 (0.3) 6.8 (0.4) 6.5 (0.4) 6.9 (0.4)
PGG 7.5 (0.5) 7.4 (1.4) 7.5 (0.5) 6.8 (1.3)
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Discussion
Spin localization is a potential oxygen-guiding mechanism which was considered 
in detail for the regio- and stereoselective addition of the first oxygen (Furse, Pratt, 
Schneider et al. 2006).   In this mechanism, an induced twist in the planar radical drives 
unpaired spin density to a specific carbon face, biasing it for oxygen addition.  While the 
16 kcal/mol barrier Furse calculated for a radical rotation is insurmountable at kT, Furse 
has proposed that smaller deviations from planarity could bias oxygen addition.  For 
example,  Mulliken spin density analysis (Figure IV-1) suggests that a 1.33:1.0 relative 
spin density localization could be achieved with a 40° out-of-plane twist, at a more 
modest energetic cost of 5 kcal/mol.  However, we observe that the trajectories only 
exhibit planar radicals (with standard deviation under 9°).  Since COX does not induce 
twist in the radical, spin localization is an extremely unlikely mechanism for COX's 
control of the second oxygen addition.
The extensive space on the bottom face of unnreactive C14 demonstrates that the 
product profile is highly dependent on a precise registration of the PGA intermediate in 
the active site.  This has lead us to reconsider the hypothesis that PGA must foreshorten 
to bring C15 into contact with Val-349, a residue which affects the stereochemistry of the 
second oxygenation (Schneider et al. 2007).  Our molecular dynamics trajectories do not 
support a foreshortening hypothesis.  We find that Gly-533 at the top of the active site 
remains 4.0 Å (+/- 0.3 Å) distant from the C20 atom of not only bound substrate, but also 
intermediates and product.  Val-349 Cβ does approach C15 when PGA is bound, and this 
could be part of the explanation for V349I's effect on stereochemistry.  Nonetheless, 
Val-349 Cβ is always more than 6.0 Å away from C15.  In the PGA trajectories, on 
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average, Cβ of Ser-530 is ~1.5 Å closer to C15 than Val-349 Cβ.  Thus, where differential 
steric occlusion of C15 may have a role in the stereochemical inversion by Ser-530 
mutants, our steric shielding analysis and simple distance measurements suggest that 
more subtle effects must be responsible for inversion in the case of V349I.
Steric shielding appears the most likely mechanism to dominate the second 
oxygenation.  This is no surprise in light of Kiefer's crystal structure observations.  What 
may be novel is our observation that the atoms in PGG2 themselves play a major role in 
steric occlusion of the allyl radical.  This observations is consistent with the fact that C13 
oxidation has been only detected as an extremely minor, putative, COX reaction product 
(Hecker et al. 1987).  Only 15-hydroxy PG isomers are found among major autoxidation 
products, and it was previously proposed that this was due to steric occlusion from the 
cyclopentane ring (Schneider et al. 2007).  Our calculations of the free space afforded by 
nearest neighbor atoms directly supports this proposal in the enzymatic context.  More 
specifically, the relatively strong occlusion of the bottom face of C15 by Ser-530 may 
indirectly explain the increased production of 15-R prostaglandins when this residue is 
mutated to Thr, Met, or Val.  Perhaps these mutations induce a register shift of PGA in the 
enzyme, or generally alter side chain packing in this region.  It is tempting to speculate 
that the failure of these mutants to entirely drive products to the 15-R stereoisomer results 
from the significant self-occlusion of the bottom face of PGG2 at the C15 position.  The 
V349I COX-2 mutant drives 60% of the product profile to 15-R.  This could be a more 
subtle effect than the Ser mutations as we find that Val-349 rarely contacts C15 as a 
nearest neighbor.  It would be interesting to test these mutations to see if the MD 
trajectories suggest interesting mechanisms for the altered oxygenation patterns.
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Earlier work by Furse convincingly argues that, in the COX system, the most 
likely route for oxygen is simply the main channel, which directly links the oxygen-
favorable membrane environment to the active site.  Short simulations, started with O2 
molecules placed near the pro-R face of the arachidonyl radical C11 atom (the site of the 
first oxygenation) usually resulted in (multiple) quick returns of O2 to the membrane, via 
the main channel.  However, in one simulation, O2 stabilized in a position near C15, 
consistent with the observation of 15R-HETE as a minor COX reaction product (Furse, 
Pratt,  Schneider et al. 2006).  Though our sample size is to still too small to impart 
statistical significance, further simulations have shown that ~5% of the time O2 will 
migrate to the top face near C15, an intriguing correlation to the ~5% 15R-HETE found 
in the reaction product mix.  As we have observed no shift of intermediates during 
different simulations, this apparently favorable binding site for O2 could well play a role 
in guiding the second oxygenation.  A comprehensive treatment of this possibility may 
require additional simulations to monitor oxygen starting from the top, pro-S, face of 
C15.  The idea of specific oxygen channeling has also been explored in 
12/15-lipoxygenase, where analysis of molecular dynamics trajectories has revealed 
oxygen channels leading to high-affinity oxygen binding sites (Saam et al. 2007). 
Perhaps these ideas will have a specific analogue in the form of a COX binding site for 
O2 above the C15 atom of bound substrate or intermediates.
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PGG2 Exit Routes in COX
Picot identifies a “long narrow channel that begins at the top of the 
cyclooxygenase channel and goes toward the dimer interface, running in the vicinity of 
the peroxidase active site.”  He does not argue that this channel exists for product 
transport.  Instead, he suggests that, as substrate binds, water might exit through this 
channel.  While early COX structures are devoid of water placement, the first high 
resolution (2.0 Å) structure of COX-1 (Gupta et al. 2004) sheds additional light on this 
channel, as a line of well-resolved waters were observed in this area.  Moreover, the 
X-ray density corresponds to a wide range of potential solvent positions, and thus 
suggests the possibility of water flow through this region.
Naming this channel “D1” in her molecular dynamics studies, Furse further 
characterized the channel as emanating from the space between Gly-533 and Gly-227. 
Her simulations found that the width of this channel is quite constant, and narrow (Furse, 
Pratt, Porter and Lybrand 2006).  These observations discount the idea that channel D1 
functions in the release of PGG2, but they are not inconsistent with D1's proposed 
function in the release of waters.  Her paper also introduces channel “D2” and reported 
that it could interconvert between open and closed states on a nanosecond time scale – 
with the more open state roughly equivalent to the D1 channel width.  Channels D1 and 
D2 are shown in Furse's graphic cutaway Figure IV-3 below:
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Figure IV-3. Channels D1 and D2 are shown from average structures from equilibrium 
trajectories of COX-2 monomer A with arachidonate bound.  (Courtesy Kristina Furse.)
Another crystallographer's proposal is that PGG2 might exit through the main 
channel constriction site, between the dimer membrane binding domains, and then transit 
through the solvent rich dimer interface (Kiefer et al. 2000).   Furse added that the dimer 
interface is rich with basic residues, and the positive electrostatic potential of the region 
could facilitate transit of PGG2.
To further explore enzyme dynamics and channel openings as the cyclooxygenase 
reaction progresses, Furse and Lybrand conducted additional simulations of COX-1 and 
COX-2 with both PGG2 and its precursor allyl radical species (PGA).  I have employed 
the channel_finder utility (methods described in previous chapter) to compare these 
systems with Furse's earlier COX simulations with bound arachidonate and arachidonyl 
pentadienyl radical.
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Channel_finder Results
A profiling of the D1 channel widths across all trajectories is shown below in 
Figure IV-4.  The histograms in these figures show counts of snapshots exhibiting various 
D1 channel widths.  As a general trend, the D1 channel opens widest when the 
arachidonyl pentadienyl radical is bound.  Though, in COX-1 monomer A, these opening 
events are more common when the allyl radical species is bound.   With PGG2 bound, the 
D1 channel radius seen in the trajectory snapshots never exceeds 1.5 Å in COX-1 – 
whereas the channel radius is routinely 0.25 Å greater for bound PGA/RAD trajectories 
(monomer A panel) and RAD/PGA trajectories (monomer B panel).  In the COX-2 
trajectories, channel D1's relative constriction with PGG2 bound is not as marked as in 
COX-1.  However, larger channel widths are sampled more frequently in the COX-2 
RAD trajectories than in the PGA or PGG2 trajectories.  
In short, these channel_finder measurements do not suggest that the D1 channel 
may be opening wider in response to bound PGG2 product, and our working 
interpretation of these data is that the D1 channels are all consistently narrow with bound 
PGG2.
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Channel Radius (Å)
Figure IV-4. Channel radii histograms for the D1 Channel.  Measurements were made on 
each monomer from the equilibrium trajectories of each COX isoform with bound 
arachidonic acid (ACD), pentadienyl radical (RAD), allyl radical (PGA) and 
prostaglandin G2 (PGG).
 
Channel_finder measurements on channel D2 (Figure IV-5 below) may suggest 
that D2 could function as a PGG2 exit route.  Monomer A of COX-1 shows a marked 
opening of the D2 channel when PGG2 is bound.  Across both COX-2 monomers, bound 
PGG2 can be associated with the largest D2 channel widths, which routinely exceed 1.5 Å 
in diameter.
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Channel Radius (Å)
Figure IV-5. Channel radii histograms for the D2 channel.  Measurements were made on 
each monomer from the equilibrium trajectories of each COX isoform with arachidonic 
acid (ACD), pentadienyl radical (RAD), allyl radical (PGA) and prostaglandin G2 (PGG) 
bound.
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Discussion
The relative instability of PGG2 suggests that its transit to the peroxidase site for 
specific reduction to PGH2 cannot be random diffusion.  Moreover, since dioxygenated 
PGG2 is somewhat bulkier and less lipophilic than arachidonic acid, we would be 
surprised if PGG2 would transit through the polar constriction site to return to the 
membrane, diffuse through the membrane to the lumen, and from there diffuse to the 
peroxidase site without chemical modification.  Though increasing catalytic efficiency 
may be a key goal for protein evolution (Albery and Knowles 1976), and “back door” 
product release mechanisms have been proposed for other systems (Gilson et al. 1994; 
Yount et al. 1995), the slow turnover of the COX reaction does not require such a “back 
door” to realize its kinetics.  However, it is arguable that nature has evolved COX with 
two reaction sites specifically because that is the most efficient structural control for the 
reaction.  And, in this case, the instability of PGG2 might require a shielded route to the 
peroxidase site as part of the system.  Perhaps a “back door” release mechanism could be 
nature's most efficient solution to this requirement, allowing PGG2 from one COX 
monomer to shuttle to the peroxidase site of the other.
The D1 channel appears relatively closed throughout these simulations, 
suggesting that it is not a likely PGG2 exit route.  This may echo an important earlier 
experimental result, where mutagenesis of Gly-533 to bulkier residues reduces COX-2's 
catalytic efficiency against arachidonate, but shorter C18 fatty acids are oxidized just as 
well by mutant enzymes (Rowlinson et al. 1999).  However, we suspect that extensive 
conformational shifts are required to release PGG2, and thus the Gly-533 mutagenesis 
effect could result entirely from unfavored registration of the arachidonate substrate.  If 
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our suspicion is correct, inference of product release routes from Gly-533 mutations 
would be an over-interpretation of these experimental results.
Furse identified the D2 channel as emanating from the top of the active site, and 
splitting into two arms.  One arm reaches to the dimer interface.  The other reaches to 
solvent, through the “top” side of the monomer.  Our channel_finder results suggest that 
D2 is a stronger candidate for product release than D1.  In our simulations, the D2 
channel opens differentially in each monomer.  But, this is not inconsistent with our 
emerging view of cyclooxygenase function, as it was recently shown that likely only one 
COX monomer is active at a time (Yuan et al. 2006).
More detailed analysis of our simulation data is still required to identify the 
structural nature of the D2 channel opening (for example whether specific protein side-
chain rotamers are implicated in the opening).  Once key residues are identified, 
mutagenesis could be suggested to attempt to alter the dynamics of the channels, and 
impact catalytic turnover.  Visual inspection suggests that side chain reorientation around 
the C15 hydroperoxide is a possible starting point for the conformational shift that creates 
the larger D2 channel – but this cannot be supported without additional work, such as 
correlation matrix analysis for the PGA vs PGG2 trajectories.  Intriguingly, the C540S and 
C313S mutations are quite distant from the COX-1 active site, but they dramatically 
reduce the activity of COX-1 (Kennedy et al. 1994).  Though these mutations have much 
less negative impact on COX-2 activity (MirAfzali et al. 2006), it is plausible that the 
serines might introduce new hydrogen bonds between secondary structural elements, and 
in doing so restrain the dynamics of channel opening.  Perhaps these deleterious 
mutations could be characterized dynamically in future simulation work.
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Many enzymes function as dimers.  It has been proposed that dimerization allows 
enzymes to be both be efficient, and allow complex kinetic responses to changes in 
substrate concentrations (Maurel and Ricard 2006).  Perhaps the symmetry of the COX 
dimer is simply nature's way of achieving these goals in the most direct manner possible. 
It is our hope that ongoing research into the mystery of COX product exit might reveal 
clues into nature's protein design strategies, and shed more light on these evolutionary 
pressures for dimerization.  Though the mystery of PGG2 exit in COX is veiled from the 
experimental techniques of structural biology, refinement of computational techniques for 
rationalizing product exit could, as Picot suggested, unveil novel strategies for inhibitor 
action or even drug design.. 
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APPENDIX A
NEW AMBER PARAMETERS
α-(R) and α-(S) methyl indomethacin ethanolamide
Atom Atom Type Charge
HO1 HO 0.412
O1 OH -0.643
C1 CT 0.127
H11 H1 0.058
H12 H1 0.058
C2 CT 0.018
H2 H1 0.104
N3 N -0.356
H3 H 0.282
C4 C 0.532
O4 O -0.535
C5 CT -0.211
H51 HC 0.098
H52 HC 0.098
C6 C* -0.029
C7 CB -0.065
C8 CA -0.144
H8 HA 0.155
C9 CA 0.126
O9 OS -0.357
C10 CA -0.158
H10 HA 0.158
C11 CA -0.215
H111 HA 0.157
C12 CN 0.038
N13 NA -0.011
Atom Atom Type Charge
C14 C 0.538
O14 O -0.503
C15 CA -0.022
C16 CA -0.147
H16 HA 0.154
C17 CA -0.049
H17 HA 0.132
C18 CA -0.026
Cl Cl -0.099
C19 CA -0.049
H19 HA 0.133
C20 CA -0.147
H20 HA 0.124
C21 CT -0.235
H211 HC 0.073
H212 HC 0.073
H213 HC 0.073
C22 CT -0.110
H221 HC 0.070
H222 HC 0.070
H223 HC 0.070
C23 CT 0.013
H231 H1 0.072
H232 H1 0.072
H233 H1 0.072
C24 CW -0.045
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C10
C9
C8
C7
C12
C11
C6
C24
N13
C22
O9C23
C5
C2
C1
O1
N3
C19
C20 C15
C16
C17C18
Cl
C14
O14
C4
O4
C21
HO1H2
H211
H213
H212
H3
H51
H52
H8
H11 H221
H223
H222
H12
H11
H231
H232
H233
H10
H16
H17
H19
H20
α-(R) and α-(S) isopropyl indomethacin ethanolamide
Atom Atom Type Charge  
HO1 HO 0.430
O1 OH -0.635
C1 CT 0.152
H11 H1 0.046
H12 H1 0.046
C2 CT -0.110
H2 H1 0.082
N3 N -0.260
H3 H 0.228
C4 C 0.396
O4 O -0.530
C5 CT -0.284
H51 HC 0.158
H52 HC 0.158
C6 C* -0.051
C7 CB -0.080
C8 CA -0.119
H8 HA 0.138
C9 CA 0.244
O9 OS -0.349
C10 CA -0.162
H10 HA 0.127
C11 CA -0.278
H111 HA 0.204
C12 CN 0.022
N13 NA -0.099
C14 C 0.616
O14 O -0.504
C15 CA -0.067
Atom Atom Type Charge 
C16 CA -0.148
H16 HA 0.143
C17 CA -0.043
H17 HA 0.132
C18 CA -0.029
Cl Cl -0.096
C19 CA -0.043
H19 HA 0.132
C20 CA -0.148
H20 HA 0.143
C22 CT -0.004
H221 HC 0.031
H222 HC 0.031
H223 HC 0.031
C23 CT -0.011
H231 H1 0.079
H232 H1 0.079
H233 H1 0.079
C24 CW 0.007
C30 CT 0.292
H30 HC 0.013
C31 CT -0.230
H313 HC 0.046
H311 HC 0.046
H312 HC 0.046
C32 CT -0.230
H321 HC 0.046
H322 HC 0.046
H323 HC 0.046
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C10
C9
C8
C7
C12
C11
C6
C24
N13
C22
O9C23
C5
C2
C1
O1
N3
C19
C20 C15
C16
C17C18
Cl
C14
O14
C4
O4
C30
HO1H2
H30
C31
C32
H3
H51
H52
H8
H11 H221
H223
H222
H12
H11
H231
H232
H233
H10
H16
H17
H19
H20
H321
H322
H323
H311
H312
H313
α-dimethyl indomethacin ethanolamide
Atom Atom Type Charge  
HO1 HO 0.412
O1 OH -0.628
C1 CT 0.120
H11 H1 0.048
H12 H1 0.048
C2 CT 0.267
N3 N -0.439
H3 H 0.306
C4 C 0.522
O4 O -0.571
C5 CT -0.074
H51 HC 0.065
H52 HC 0.065
C6 C* -0.058
C7 CB -0.056
C8 CA -0.169
H8 HA 0.160
C9 CA 0.199
O9 OS -0.388
C10 CA -0.168
H10 HA 0.162
C11 CA -0.252
H111 HA 0.178
C12 CN 0.026
N13 NA -0.061
C14 C 0.625
O14 O -0.512
C15 CA -0.051
Atom Atom Type Charge
C16 CA -0.156
H16 HA 0.148
C17 CA -0.046
H17 HA 0.134
C18 CA -0.032
Cl Cl -0.096
C19 CA -0.046
H19 HA 0.134
C20 CA -0.156
H20 HA 0.148
C22 CT -0.250
H221 HC 0.105
H222 HC 0.105
H223 HC 0.105
C23 CT -0.001
H231 H1 0.075
H232 H1 0.075
H233 H1 0.075
C24 CW -0.019
C31 CT -0.206
H311 HC 0.056
H312 HC 0.056
H313 HC 0.056
C32 CT -0.206
H321 HC 0.056
H322 HC 0.056
H323 HC 0.056
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C10
C9
C8
C7
C12
C11
C6
C24
N13
C22
O9C23
C5
C2
C1
O1
N3
C19
C20 C15
C16
C17C18
Cl
C14
O14
C4
O4
C31
HO1C32
H311
H313
H312
H3
H51
H52
H8
H11 H221
H223
H222
H12
H11
H231
H232
H233
H10
H16
H17
H19
H20
H321
H322 H323
Potential Function Parameters
Section 1. Parameters for Bond Terms
Ebond = Kr(r – r0)2
Kr r0
CW-CT 317.8      1.490 
CA-OS 431.4      1.380
 
Section 2. Parameters for Bond Angle Terms
Eangle = Kθ(θ – θ0)2
Kθ θ0
C-CT-C* 70. 111.8
C*-CW-CT 70 128.7 
CW-CT-HC50 111.0
CW-NA-C 70 125.8
CT-CW-NA70 122.8
NA-C –CA 70 124.6
CN-NA-C 70 125.6
CA-CA-OS 70 119.0
CA-OS-CT 60 109.9 
O -C –CA 80 118.4
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Section 3. Parameters for Torsion Angle Terms
Etors = ( PK / IDIVF ) * ( 1 + cos( PN * φ - PHASE) )
IDIVF PK PHASE PN 
C*-CW-CT-HC  1 0.0 0. 3.
NA-CW-CT-HC 1 0.0 0. 3.
X -CA-OS-X  2 1.0 180. 2.
Section 4. Parameters for Improper Torsion Angle Terms
Etors = ( PK ) * ( 1 + cos( PN * φ - PHASE) )
PK PHASE PN 
NA-CA-CN-CB 1.1 180. 2.
CA-C*-CB-CN 1.1 180. 2.
CW-CN-NA-C 1.1 180. 2.
C -CA-CA-CA 1.1 180. 2.
C*-CT-CW-NA 1.1 180. 2.
CA-OS-CA-CA 1.1 180. 2.
CA-Cl-CA-CA 1.1 180. 2.
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